FOOD LABELING

FDA Needs to Reassess Its Approach to Protecting Consumers from False or Misleading Claims
Why GAO Did This Study

The Food and Drug Administration (FDA) oversees federal requirements to prohibit false or misleading food labels; the Federal Trade Commission enforces the prohibition against false or misleading advertising. By statute, health claims on food labels must have significant scientific agreement, but in 2002, in response to a court decision, FDA decided to allow qualified health claims with less scientific support. Structure/function claims refer to a food’s effect on body structure or function and are also used on food. Congress directed GAO to study FDA’s implementation of qualified health claims for food. GAO examined (1) the results of FDA’s efforts to allow the use of qualified health claims and oversight of these claims and (2) consumers’ understanding of the claims. GAO also examined FDA’s oversight of structure/function claims. GAO reviewed FDA documents and consumer studies and interviewed stakeholders from health, medical, industry, and consumer groups.

What GAO Found

FDA’s efforts to protect consumers from false or misleading claims are conducted in a complex and challenging legal and regulatory environment. From 2002, when FDA announced its decision to allow qualified health claims on food labels—following a court decision involving its authority to regulate dietary supplements—through September 2010, FDA received 16 petitions from companies proposing 60 claims on food labels. After reviewing the scientific evidence presented in the petitions, FDA determined that there was enough credible scientific evidence for the agency to allow the use of 12 qualified health claims, by modifying language to qualify the claims and characterize in detail the strengths and limitations of the scientific support for those claims. In overseeing qualified health claims for food labels, FDA has issued two warning letters to food companies—both in 2010—for citing health benefits that were not in the allowed qualified health claims or supported by scientific evidence.

Research showed, and stakeholders indicated, that consumers find it difficult to understand the differences between health claims with significant scientific agreement and the lower level of scientific support for qualified health claims. Research also showed that consumers find it difficult to distinguish among the many different types of claims on food labels, including health claims, qualified health claims, and structure/function claims.

FDA data indicate that companies now minimally use qualified health claims on foods but more widely use structure/function claims to convey their foods’ health benefits. Companies’ use of structure/function claims is subject to the general statutory requirement that labeling not be false or misleading. However, FDA has not given companies guidance on the scientific support needed to prevent false or misleading information for a structure/function claim for food or given its inspectors instructions for identifying potentially false or misleading information in such claims when examining food labels as part of food facility compliance inspections. Even if FDA were to provide such guidance, structure/function claims pose a serious oversight dilemma for the agency. That is because FDA—unlike the Federal Trade Commission (FTC), which can require companies to submit any relevant evidence as part of an investigation of whether claims are substantiated—does not have the ability to compel companies to turn over their substantiation documents. GAO’s work indicates that FDA’s efforts to meet that burden are hampered by the lack of access to the evidence that a company relies on to make such a claim. In particular, while FDA may ask a company to provide its scientific support for a claim, FDA does not have express legal authority to compel the company to provide such information. FTC, on the other hand, which is responsible for protecting consumers from false advertising generally, has the authority to compel companies to provide the support. FTC officials said that the Commission would have difficulty taking enforcement actions against companies for alleged false structure/function claims on food labels and in advertisements without access to companies’ proprietary market and scientific research.

What GAO Recommends

GAO recommends FDA identify and request from Congress authorities to access companies’ evidence for potentially false or misleading structure/function claims on food to establish scientific support, provide guidance to industry on the evidence it needs to support such claims, and provide direction to FDA inspectors to help identify claims for further review. FDA generally agreed with the first two recommendations but found the third to be impractical; GAO clarified that recommendation.

View GAO-11-102 or key components.
For more information, contact Lisa Shames at (202) 512-3841 or shamesl@gao.gov.
### Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Letter</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Background</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>FDA Has Allowed the Use of 12 Qualified Health Claims on Food Labels and Provided Limited Oversight for These Claims</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Consumers Have Difficulty Understanding the Level of Scientific Support for Qualified Health Claims and How These Claims Differ from Other Claims</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Industry More Widely Uses Structure/Function Claims on Food with Minimal FDA Oversight, but FTC Has Taken Some Action When These Claims Were Deceptive</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Conclusions</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Recommendations for Executive Action</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Agency Comments and Our Response</td>
<td>28</td>
</tr>
<tr>
<td><strong>Appendix I</strong></td>
<td>FDA’s Administration of Health Claims in Response to Pearson v. Shalala</td>
<td>31</td>
</tr>
<tr>
<td><strong>Appendix II</strong></td>
<td>Objectives, Scope, and Methodology</td>
<td>37</td>
</tr>
<tr>
<td><strong>Appendix III</strong></td>
<td>Types of Claims FDA Recognizes, and Industry May Use, on Food</td>
<td>40</td>
</tr>
<tr>
<td><strong>Appendix IV</strong></td>
<td>Health Claims That May Be Used On Food Labels</td>
<td>42</td>
</tr>
<tr>
<td><strong>Appendix V</strong></td>
<td>Warning Letters Issued for Claim Violations on Food Labels and Web Sites, December 2009 through February 2010</td>
<td>47</td>
</tr>
<tr>
<td><strong>Appendix VI</strong></td>
<td>Comments from the Department of Health and Human Services</td>
<td>50</td>
</tr>
</tbody>
</table>
### Appendix VII  
**GAO Contact and Staff Acknowledgments**  

#### Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1</td>
<td>Twelve Qualified Health Claims Allowed for Use on Food, through September 2010</td>
<td>10</td>
</tr>
<tr>
<td>Table 2</td>
<td>Petitions and Proposed Qualified Health Claims for Food Labeling Submitted Annually, Calendar Year 2002 through September 30, 2010</td>
<td>12</td>
</tr>
<tr>
<td>Table 3</td>
<td>Types of Claims FDA Found on Food Labels in Its Survey of Grocery Stores</td>
<td>13</td>
</tr>
<tr>
<td>Table 4</td>
<td>Two FDA Warning Letters Issued in February 2010 Regarding Qualified Health Claims</td>
<td>15</td>
</tr>
<tr>
<td>Table 5</td>
<td>Twelve Health Claims Based on Significant Scientific Agreement That May Be Used on Food Labels</td>
<td>42</td>
</tr>
<tr>
<td>Table 6</td>
<td>Five Health Claims Based on Authoritative Statements That May Be Used on Food Labels</td>
<td>46</td>
</tr>
<tr>
<td>Table 7</td>
<td>Other Warning Letters and the Untitled Letter FDA Issued for Labeling Claim Violations, December 2009 through February 2010</td>
<td>47</td>
</tr>
</tbody>
</table>
Abbreviations

CFSAN     Center for Food Safety and Applied Nutrition  
EU        European Union  
FDA       Food and Drug Administration  
FLAPS     Food Label and Package Survey  
FTC       Federal Trade Commission  
FTE       full-time equivalent  
g         gram  
HHS       Department of Health and Human Services  
IOM       Institute of Medicine  
LDL       low-density lipoprotein  
mg        milligram  
NLEA      Nutrition Labeling and Education Act  
RACC      referenced amount customarily consumed  

This is a work of the U.S. government and is not subject to copyright protection in the United States. The published product may be reproduced and distributed in its entirety without further permission from GAO. However, because this work may contain copyrighted images or other material, permission from the copyright holder may be necessary if you wish to reproduce this material separately.
January 14, 2011

The Honorable Daniel K. Inouye
The Honorable Thad Cochran
United States Senate

The Honorable Harold Rogers
Chairman
The Honorable Norman D. Dicks
Ranking Member
Committee on Appropriations
House of Representatives

Consumers increasingly seek information on food labels to help them make healthy food choices, and they rely on federal agencies to ensure that such information is truthful. Food companies may use health- and/or nutrient-related claims on food labels to appeal to consumers, distinguish their products from their competitors’, and otherwise increase their sales. However, when those claims are false or misleading, consumers’ efforts to select healthy food may be undermined. Under federal statutes and regulations, health claims on food must either (1) be authorized by FDA upon a determination that “significant scientific agreement” exists among qualified experts that the totality of publicly available scientific evidence supports the claims or (2) be based on an authoritative statement of a scientific body of the federal government or the National Academy of Sciences.

Through separate statutes, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) share jurisdiction over health- and nutrient-related claims made by food manufacturers. FDA oversees federal food labeling requirements that prohibit, among other things, food labeling that is false or misleading; FTC oversees federal consumer protection requirements that prohibit, among other things, deceptive acts or practices in advertising, including food advertising. Under a memorandum of understanding, the two agencies agreed that FDA has primary responsibility for food labeling and FTC has primary responsibility for food advertising. FTC has recently emphasized that health claims on food must be adequately substantiated and presented in a manner that is truthful and not deceptive. FDA regulations allow companies to use an authorized health claim on a label or petition FDA for authorization of a new health claim. To ensure health claims have the proper support, FDA
analyzes and reviews research on nutrition and the role of food in maintaining health.

FDA categorizes health- and nutrient-related claims on food labels as follows:

- **Health claims** characterize the relationship of any substance to a disease or health-related condition (e.g., diets low in sodium may reduce the risk of high blood pressure, a disease associated with many factors).

- **Structure/function claims** describe the role of, or characterize the mechanism by which, a nutrient affects a body structure or function (e.g., calcium helps build strong bones).

- **Nutrient content claims** characterize the level of a nutrient in a food (e.g., good source of vitamin C).

Qualified health claims are health claims that characterize the relationship of a food component to a disease or health-related condition, as modified with a disclaimer or otherwise qualified by FDA to characterize the strengths and limitations of the scientific support to address the claim's potentially misleading nature. For example, the following is a qualified health claim allowed by FDA characterizing the relationship between the consumption of tomatoes and the risk of gastric cancer:¹ “Four studies did not show that tomato intake reduces the risk of gastric cancer, but three studies suggest that tomato intake may reduce this risk. Based on these studies, FDA concludes that it is unlikely that tomatoes reduce the risk of gastric cancer.” Qualified health claims for food are not provided for in statute. Instead, they came about as a consequence of FDA’s decisions following a 1999 federal appeals court ruling (*Pearson v. Shalala*). The court held that the First Amendment does not permit FDA to prohibit a potentially misleading health claim on a dietary supplement label unless FDA considers whether qualifying language on the label could negate the potentially misleading nature of the claim. (Dietary supplements are products that contain certain dietary ingredients such as vitamins, minerals, or herbs, intended to supplement the diet, and are labeled as dietary supplements.)

¹In this report we use the word “allow” to describe FDA’s assertion to companies that the agency will consider exercising its discretion to not take enforcement action against the company for making a certain health claim so long as that claim is made in accordance with criteria provided by FDA.
After the court ruling, in 2000, FDA announced an interim enforcement strategy to allow companies to petition the agency for qualified health claims on dietary supplements and established criteria for the agency to consider in exercising its enforcement discretion to not take actions. In 2002, FDA announced its decision to expand this approach to include qualified health claims on conventional food as well. The next year, FDA issued guidance to industry on procedures for petitioning the agency for qualified health claims for food. Once FDA announces, on the basis of its review of scientific evidence, that it intends to consider exercising its enforcement discretion for the use of a qualified health claim, any food company that meets the same criteria with the same food may use the claim.

In 2008, we reported that stakeholders from health, consumer, and medical groups advocated eliminating qualified health claims on food labels because they confused and misled consumers and might encourage consumption of foods with few or no health benefits.\(^2\)

The Subcommittees on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Senate and House Committees on Appropriations, directed that we study issues regarding FDA’s implementation of qualified health claims on food.\(^3\) Specifically, this report examines (1) the results of FDA’s efforts to allow the use of qualified health claims on food, and its oversight of these claims and (2) what is known about consumers’ understanding of qualified health claims on food. In addition, the report examines industry’s use of structure/function claims on food and FDA’s oversight of these claims. Appendix I provides updates to information we reported in 2008 on FDA’s implementation and administration of health claims, including qualified health claims, in response to *Pearson v. Shalala*.

The term “food” is used throughout this report to mean “conventional food,” not to include dietary supplements or animal feed. To determine the results of FDA’s efforts to allow the use of qualified health claims on food, we assessed FDA data and documentation, including industry petitions.

---


and FDA guidance; reviewed research on companies' use of health- and nutrient-related claims on foods; and obtained the views of industry, FDA, and others on the advantages and disadvantages of using qualified health claims. To determine FDA’s oversight of qualified health claims, we analyzed FDA guidance and related documents on the enforcement of food labeling claims, analyzed warning letters and other FDA actions, and compared and contrasted FDA’s and FTC’s responsibilities and authorities with respect to food labeling and advertising claims. To determine what is known about consumers’ understanding of qualified health claims on conventional food labels, we reviewed research by FDA and others on consumers’ understanding of such claims and interviewed stakeholders—researchers and industry and consumer, medical, and health groups we identified with input from the National Academies’ Institute of Medicine, and FDA officials—for their views on what the research demonstrates about consumer perception. To examine industry’s use of structure/function claims on food labels and FDA’s oversight of these claims, we assessed FDA data, documentation, and studies on industry’s use of these claims, and efforts to oversee their use. We also discussed the use of structure/function claims with Canadian and European Union officials. We also examined FTC’s actions to correct structure/function claims it found to be deceptive in food advertising. We assessed the quality of the studies, including how the data they contained were initially developed and analyzed, and found those data to be of sufficient quality and reliability for the purposes used.

We conducted this performance audit from January 2010 through December 2010 in accordance with generally accepted government auditing standards. Those standards require that we plan and perform the audit to obtain sufficient, appropriate evidence to provide a reasonable basis for our findings and conclusions based on our audit objectives. We believe that the evidence obtained provides a reasonable basis for our findings and conclusions based on our audit objectives. Appendix II contains more detailed information on our objectives, scope, and methodology.

The following sections discuss (1) the statutes, regulations, and guidance that underpin FDA’s framework for overseeing claims on food labels and (2) FDA’s organization for overseeing food labels.
### FDA’s Framework for Overseeing Claims on Food Labels

FDA’s framework for overseeing food labeling is based on statutes and FDA regulations and guidance. Specifically, the Federal Food, Drug, and Cosmetic Act prohibits the misbranding of food, which includes, among other things, food labeling that is false or misleading. The Nutrition Labeling and Education Act of 1990 (NLEA), amended the Federal Food, Drug, and Cosmetic Act to require that health claims for food labels be authorized by FDA following a determination by FDA that “significant scientific agreement” exists among qualified experts that the totality of publicly available scientific evidence supports the claims. According to FDA documents, the primary goals of NLEA were to (1) make nutrition information available to assist consumers in selecting foods that could lead to healthier diets; (2) eliminate consumer confusion by establishing definitions for nutrient content claims that are consistent and that consumers could rely on; (3) help consumers maintain healthy dietary practices and protect them from unfounded health claims, so a health claim used on a product would be one that consumers could rely on to give them truthful and not misleading information; and (4) encourage product innovation by developing and marketing nutritionally improved food.

FDA took several actions in response to the *Pearson v. Shalala* ruling, such as issuing guidance on how companies should submit petitions to FDA and how FDA would review the scientific evidence and exercise its enforcement discretion. (See app. I for information on FDA’s implementation and administration of health claims in response to *Pearson v. Shalala*.) In 2003, FDA issued interim guidance to industry for submitting petitions for qualified health claims on food labels and for reviewing the scientific evidence for those claims, and explained its intention to consider exercising its enforcement discretion to not take enforcement actions against companies that use qualified health claims as FDA specified. In 2006 FDA issued additional guidance to industry that described how the agency would review the scientific evidence industry submitted in support of the proposed qualified health claims. FDA specified that a petition for qualified health claims should, among other things, (1) identify the relationship between the substance and the disease in the United States and demonstrate that the substance is a food, a food ingredient, or food component that has been shown to be safe and lawful at levels necessary to justify a claim; (2) propose a claim—a statement that describes the benefit of the food substance—and (3) present scientific evidence that supports the claim, including copies of computer literature searches on studies and all research articles supporting the claim. Petitions may be submitted by individuals, food manufacturing companies,
food distributors, trade or professional associations, or a combination of these. For this report, we generally refer to petitioners as companies.

As specified in its 2003 and 2006 guidance, FDA conveys its determinations to allow qualified health claims and its intention to exercise enforcement discretion with respect to certain requirements of the Federal Food, Drug, and Cosmetic Act to petitioners. In letters to the companies announcing its intention to exercise enforcement discretion, FDA stipulates the wording of the qualified health claims and any conditions on their use. FDA also alerts petitioners that the claims must meet the general requirements for FDA’s labeling regulations for health claims, except for the requirement that the evidence for the claim meet the significant scientific agreement standard and that the claim be made in accordance with an authorizing regulation. The qualified health claims and all conditions regarding their use are posted on FDA’s Web site to alert all food companies that the claims are available for use without further FDA review or approval. When FDA decides to deny a proposed claim, it describes its review of the scientific evidence and the rationale for its decision in correspondence to the petitioners and posts the letters conveying those denials on its Web site. In addition, in 2009 FDA issued final guidance for industry describing its process for the scientific review of health claims, including qualified health claims, in which it stated that it would reevaluate health claims and qualified health claims as new scientific evidence emerged.

As with health claims, companies also use structure/function claims to convey the health benefits of their foods or dietary supplements. The Dietary Supplement Health and Education Act of 1994 established special requirements for structure/function claims on dietary supplement labels. Specifically, under the act, if a dietary supplement label includes a structure/function claim, it must have a disclaimer stating, “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.” Products intended for use in the diagnosis, mitigation, treatment, cure, or prevention of a disease are considered drugs under the Federal Food, Drug, and Cosmetic Act. In addition, a structure/function claim on a dietary supplement label must have substantiation and either (1) claim a benefit related to a classical nutrient deficiency disease and disclose the prevalence of such disease in the United States, (2) describe the role of a nutrient or dietary ingredient intended to affect the structure or function in humans, (3) characterize the documented mechanism by which a
nutrient or dietary ingredient acts to maintain such structure or function, or (4) describe general well-being from consumption of a nutrient or dietary ingredient. These requirements do not apply to structure/function claims on food labels. However, the use of such claims for food is subject to the Federal Food, Drug, and Cosmetic Act’s requirement that labeling not be false or misleading, and FDA has not issued guidance to companies regarding the proper use of structure/function claims on food labels.

Appendix III provides information on the different types of health- and nutrient-related claims that may be found on food labels. Appendix IV presents the 12 health claims for food that have significant scientific agreement and 5 health claims for food that are based on authoritative statements.

FDA’s Organization for Overseeing Food Labels

Within FDA, food labeling is under the jurisdiction of the Office of Foods’ Center for Food Safety and Applied Nutrition (CFSAN). Within CFSAN, the Office of Nutrition, Labeling and Dietary Supplements is responsible for reviewing qualified health claim petitions, and the Office of Regulation, Policy, and Social Sciences conducts consumer research on health claims and qualified health claims. In addition, for more than 30 years, FDA has conducted surveys and studies of labels on processed, packaged food. In 2010 FDA reported the results of its most recent Food Label and Package Survey (FLAPS) of claims used on food packages in grocery stores nationwide. The most recent FLAPS, conducted during 2006 and 2007, was the 13th in a series of labeling studies and the first to include qualified health claims.

FDA’s Office of Regulatory Affairs carries out food safety and labeling compliance inspections and enforcement activities. When the office identifies a labeling violation, FDA may send a warning letter—a notice that an enforcement action may be forthcoming if corrections are not made—or, for a less serious violation, an untitled letter communicating that corrective action is needed. At any point during the oversight process, FDA may hold a regulatory meeting with the company to resolve the labeling violation. For a serious labeling violation, FDA may ask a company to voluntarily recall food that has already entered the

---

4 Manufacturers of dietary supplements making structure/function claims must notify FDA no later than 30 days after the first marketing of the dietary supplement with such a claim statement.
distribution chain.\(^5\) When a violation is not corrected, FDA may initiate actions to seize and remove the food from the marketplace (seizure) or enjoin a company from continuing the practice that violates food labeling statutes and regulations (an injunction). For food imported from a foreign country, FDA may issue an import refusal to prevent a shipment with a serious labeling violation from entering the United States. FDA may also release a shipment “with comment”—that is, allow the shipment with a labeling violation to enter the United States with a notice to the importer that subsequent shipments might be refused entry if the violation is not corrected. In addition, FDA maintains “import alerts” that flag entries of imported foods that appear to be violative and may be detained, based on, for example, significant recurring or unusual violations.

Since January 2007, federal oversight of food safety has been on GAO’s high-risk list of government programs that need broad-based transformation to achieve greater economy, efficiency, effectiveness, accountability, and sustainability.\(^6\) Our September 2008 report on food labeling discusses in detail FDA’s oversight of food labeling laws and regulations.\(^7\) As we reported, FDA had little assurance that companies complied with food labeling laws and regulations for preventing false or misleading labeling, among other things. We found weaknesses in FDA’s oversight and use of data and resources. For example, although FDA’s inspection guidance directs inspectors to examine three product labels during a food facility inspection, FDA did not have reliable data on the number of labels examined or which inspections included label examinations. In following up on our recommendations in that report, we found that FDA has taken action on four of the report’s seven recommendations and plans to continue addressing our remaining recommendations for better leveraging its resources and staff as resources become available.

\(^5\)The Federal Food, Drug, and Cosmetic Act, as amended by the FDA Food Safety Modernization Act on January 4, 2011, authorized FDA to order a mandatory recall if it determines there is a reasonable probability that an article of food is (1) adulterated or (2) misbranded with regard to a major food allergen, and the use of or exposure to the food will cause serious adverse health consequences or death in humans or animals.


\(^7\)GAO-08-597.
Since 2002, when it announced its decision to allow companies to petition the agency for qualified health claims on food, FDA has determined that it would allow the use of 12 qualified health claims for food, and spent at least an estimated $12.8 million since 2000 on health claim and qualified health claim activities. FDA data indicate that companies' interest in qualified health claims has slowed. In addition, FDA has exercised limited oversight of industry's use of these claims.

From 2002 through September 2010, FDA received 16 petitions proposing 60 claims, which it considered for qualified health claims on food labels. After reviewing the scientific evidence presented in the petitions, FDA determined that there was enough credible scientific evidence for the agency to modify 12 health claims with qualifying language to characterize in detail the strength and limitations of the scientific support for those claims. In letters to petitioners, FDA stated that it intended to consider exercising its enforcement discretion to not enforce certain requirements of the Federal Food, Drug, and Cosmetic Act and its implementing regulations for these qualified health claims. The claims had to meet the other requirements for health claims and any claim-specific conditions stipulated by FDA. FDA posted the 12 qualified health claims and conditions for their use on its Web site. Table 1 lists the 12 qualified health claims that are available for use on food labels.

Five of the 16 petitions were initially submitted as health claim petitions under the significant scientific agreement standards but were converted to qualified health claim petitions at the request of the petitioners. All 16 petitions proposed claims for use on food labels, although some were for use on both food and dietary supplement labels.
<table>
<thead>
<tr>
<th>Food/disease risk</th>
<th>Qualified health claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tomatoes/reduced risk for prostate cancer</td>
<td>Very limited and preliminary scientific research suggests that eating one-half to one cup of tomatoes and/or tomato sauce a week may reduce the risk of prostate cancer. FDA concludes that there is little scientific evidence supporting this claim.</td>
</tr>
<tr>
<td>Tomatoes/reduced risk for ovarian cancer</td>
<td>One study suggests that consumption of tomato sauce two times per week may reduce the risk of ovarian cancer, while this same study shows that consumption of tomatoes or tomato juice had no effect on ovarian cancer risk. FDA concludes that it is highly uncertain that tomato sauce reduces the risk of ovarian cancer.</td>
</tr>
<tr>
<td>Tomatoes/reduced risk for gastric cancer</td>
<td>Four studies did not show that tomato intake reduces the risk of gastric cancer, but three studies suggest that tomato intake may reduce this risk. Based on these studies, FDA concludes that it is unlikely that tomatoes reduce the risk of gastric cancer.</td>
</tr>
<tr>
<td>Tomatoes/reduced risk for pancreatic cancer</td>
<td>One study suggests that consuming tomatoes does not reduce the risk of pancreatic cancer, but one weaker, more limited study suggests that consuming tomatoes may reduce this risk. Based on these studies, FDA concludes that it is highly unlikely that tomatoes reduce the risk of pancreatic cancer.</td>
</tr>
<tr>
<td>Green tea/reduced risk for breast cancer</td>
<td>Two studies do not show that drinking green tea reduces the risk of breast cancer in women, but one weaker, more limited study suggests that drinking green tea may reduce this risk. Based on these studies, FDA concludes that it is highly unlikely that green tea reduces the risk of breast cancer.</td>
</tr>
<tr>
<td>Green tea/reduced risk for prostate cancer</td>
<td>One weak and limited study does not show that drinking green tea reduces the risk of prostate cancer, but another weak and limited study suggests that drinking green tea may reduce this risk. Based on these studies, FDA concludes that it is highly unlikely that green tea reduces the risk of prostate cancer.</td>
</tr>
<tr>
<td>Nuts/reduced risk for heart disease</td>
<td>Scientific evidence suggests but does not prove that eating 1.5 ounces per day of most nuts [such as name of specific nut] as part of a diet low in saturated fat and cholesterol may reduce the risk of heart disease. [See nutrition information for fat content.]</td>
</tr>
<tr>
<td>Walnuts/reduced risk for coronary heart disease</td>
<td>Supportive but not conclusive research shows that eating 1.5 ounces per day of walnuts, as part of a low saturated fat and low cholesterol diet and not resulting in increased caloric intake may reduce the risk of coronary heart disease. See nutrition information for fat [and calorie] content.</td>
</tr>
<tr>
<td>Omega-3 fatty acids/reduced risk for coronary heart disease</td>
<td>Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease. One serving of [Name of the food] provides [ ] gram of EPA and DHA omega-3 fatty acids. [See nutrition information for total fat, saturated fat, and cholesterol content.]</td>
</tr>
<tr>
<td>Monounsaturated fatty acids from olive oil/reduced risk for coronary heart disease</td>
<td>Limited and not conclusive scientific evidence suggests that eating about 2 tablespoons (23 grams) of olive oil daily may reduce the risk of coronary heart disease due to the monounsaturated fat in olive oil. To achieve this possible benefit, olive oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of olive oil.</td>
</tr>
<tr>
<td>Unsaturated fatty acids from canola oil/reduced risk for coronary heart disease</td>
<td>Limited and not conclusive scientific evidence suggests that eating about 1½ tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil.</td>
</tr>
</tbody>
</table>
### Food/disease risk

<table>
<thead>
<tr>
<th>Qualified health claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corn oil/reduced risk for heart disease</td>
</tr>
</tbody>
</table>

Source: FDA.

Note: The 12 claims are based on 15 proposed claims.

“The omega-3 fatty acids, EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), are components of some fatty fish (primarily cold-water fish), fish oils, other foods (e.g., seaweed), and food ingredients (e.g., algal oils).

In addition, FDA denied 42 of the 60 proposed claims. In letters to the petitioners conveying these decisions, FDA discussed its consideration of the specific scientific evidence submitted to support the claims it denied and how it reached a final determination that “neither a disclaimer nor qualifying language would suffice to prevent consumer deception” if the claims were used. FDA attributed each of the denials to the lack of credible scientific evidence to support the claim. In addition to the 42 claims that were denied and the 15 used to develop the 12 allowed qualified health claims, 1 proposed claim is pending, and 2 were withdrawn.

### FDA Officials Estimated Spending at Least $12.8 Million to Implement and Administer Health Claims and Qualified Health Claims since 2000

Since FDA decided to allow companies to petition the agency for qualified health claims, it has carried out a number of activities to implement the framework for qualifying claims and making scientific determinations on proposed claims. These activities included, among others, developing guidance for industry and FDA staff; carrying out research; and analyzing studies, surveys, and other scientific evidence submitted in support of the proposed claims. FDA officials estimated that, for the 11 fiscal years 2000 through 2010, CFSAN has spent at least $12.8 million, including expenses for nearly 88.7 full-time equivalent (FTE) staff, to implement and administer health claims and qualified health claims. FDA officials provided estimates because they said that the agency does not maintain data on expenditures and staff charges for the different responsibilities performed by CFSAN’s Office of Nutrition, Labeling, and Dietary Supplements staff. However, for offices outside the Office of Nutrition, Labeling, and Dietary Supplements that worked on qualified health claim activities for food labeling, such as the Office of the Chief Counsel, FDA officials could not provide estimates with any degree of confidence on expenditures and staff years spent on activities related to health or qualified health claims since 2000. It is also unclear what portion of the...
estimated $12.8 million was used solely for qualified health claim activities and what portion was used for regulatory activities on the 12 health claims for food. However, in FDA’s technical comments on a draft of this report, the agency pointed out that many of the health claims assessed under the significant scientific agreement standard were completed prior to 2000.\footnote{FDA noted in its comments that in each of the last 10 years, it has accomplished its work related to health claims and qualified health claims by supporting an average 8.1 FTEs (at 1,700 hours per FTE) per year at a cost of approximately $1 million per year.}

### Companies Minimally Use Qualified Health Claims

FDA data and other research indicate that companies’ interest in qualified health claims has slowed. FDA’s and industry’s initial expectation of a flood of petitions for qualified health claims on food was never realized, according to agency officials. As shown in table 2, three-quarters (45 of 60) of the proposed claims for food labels were submitted in five petitions in 2004, and only one petition with one proposed claim was submitted after 2006.

<table>
<thead>
<tr>
<th>Calendar year</th>
<th>Number of petitions submitted</th>
<th>Number of proposed claims submitted</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2003</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>2004</td>
<td>5</td>
<td>45</td>
</tr>
<tr>
<td>2005</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>2006</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>2007</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2008</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2009</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>2010</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>16</strong></td>
<td><strong>60</strong></td>
</tr>
</tbody>
</table>

Source: GAO analysis of FDA data.

In addition, research by FDA and others shows that companies are making minimal use of qualified health claims. In 2010, FDA reported its latest
FLAPS results of claims on food labels in grocery stores. As shown in table 3, few food labels—only 0.4 percent—had qualified health claims.

<table>
<thead>
<tr>
<th>Claim type</th>
<th>Percentage of labels with claim type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qualified health claim</td>
<td>0.4</td>
</tr>
<tr>
<td>Health claim (based on significant scientific agreement or an authoritative source)</td>
<td>4.3</td>
</tr>
<tr>
<td>Structure/function claim</td>
<td>5.5</td>
</tr>
<tr>
<td>Other implied nutrient content claim</td>
<td>5.6</td>
</tr>
<tr>
<td>“Healthy” claim (an implied nutrient content claim)</td>
<td>7.6</td>
</tr>
<tr>
<td>Significant source claim</td>
<td>20.5</td>
</tr>
<tr>
<td>Nutrient content claim</td>
<td>53.2</td>
</tr>
</tbody>
</table>


Note: A sampled label may have had multiple claims. The claim types are those used by FDA in the survey.

* A type of nutrient content claim.

Moreover, according to a 2009 study by West Virginia University researchers, companies that could have used qualified health claims more often did not. This study focused on labels of foods eligible to use qualified health claims. Specifically, it found that only 4.6 percent of food packages eligible for a qualified health claim actually used one. Instead, companies chose to use a different type of claim to convey the health or nutritional benefits of their food.

FDA Oversight of Qualified Health Claims Is Limited

FDA continues to use its enforcement discretion for qualified health claims and has not taken enforcement actions against companies for violations involving these claims. However, as part of an oversight

---

10 According to the FLAPS study, FDA analyzed the 2005 AC Nielsen Strategic Planner database to identify a sample of 3,000 U.S. supermarkets with over $2 million in annual revenue, across all geographic areas. Only products available in at least 2 percent of the stores in the retail market were considered. The data can be generalized to 80 to 85 percent (plus or minus 3 percent) of the retail food sales.

FDA initiated a food labeling compliance initiative, issuing 17 warning letters to food companies from December 2009 to February 2010, including 2 for violations related to their use of qualified health claims. FDA officials stated that to the best of their knowledge, these were the first warning letters the agency had issued regarding qualified health claims on food.

The two warning letters for qualified health claims were issued to Fleminger, Inc., for claims about green tea, and Diamond Food, Inc., for claims about walnuts. As shown in table 4, according to FDA's warning letters, the companies (1) failed to use the specific qualified health claims statements allowed by FDA and (2) added language that was not supported by scientific evidence. Specifically, according to FDA's letter to Fleminger, Inc., the company's Web site had stated that high consumption of green tea is associated with reduced risks for cancer of the esophagus, stomach, colon, rectum, pancreas, urinary bladder, lung, liver and ovary—claims regarding diseases that FDA did not find support for, and did not include in the qualified health claims. Noting that the statements on the Web site altered the meaning of the qualified health claim language and misrepresented FDA's conclusions, FDA found that the statements caused the products to be misbranded in violation of the Federal Food, Drug, and Cosmetic Act. In its warning letter to Diamond Food, Inc., FDA said, among other things, that the product label contained health claims that were not authorized by FDA, in violation of the Federal Food, Drug, and Cosmetic Act. The label had the phrase "OMEGA-3 2.5 g per serving" and heart symbols adjacent to information about the amount of omega-3 in the product—implying that omega-3 reduces the risk of coronary heart disease and that the relationship between walnuts and coronary heart disease is related to the omega-3 fatty acid content of walnuts. However, as FDA's letter points out, there is not sufficient evidence to identify omega-3 fatty acid as the substance in walnuts that reduces the risk of coronary heart disease.
Table 4: Two FDA Warning Letters Issued in February 2010 Regarding Qualified Health Claims

<table>
<thead>
<tr>
<th>Company, date of warning letter, and product cited for violation</th>
<th>Qualified health claims allowed for product</th>
<th>Excerpts from the warning letter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fleminger, Inc. (Feb. 22, 2010) TeaForHealth™ green tea products Dr. Lee's TeaForHealth® 710EGCG™ inabottle™ Green Tea and TeaForHealth® 710EGCG™ Ready-To-Drink Natural Brewed Green Tea</td>
<td>1. &quot;Two studies do not show that drinking green tea reduces the risk of breast cancer in women, but one weaker, more limited study suggests that drinking green tea may reduce this risk. Based on these studies, FDA concludes that it is highly unlikely that green tea reduces the risk of breast cancer.&quot; 2. &quot;One weak and limited study does not show that drinking green tea reduces the risk of prostate cancer, but another weak and limited study suggests that drinking green tea may reduce this risk. Based on these studies, FDA concludes that it is highly unlikely that green tea reduces the risk of prostate cancer.&quot;</td>
<td>The letter states that the following claims, presented on the company’s Web sites, were unauthorized and not consistent with either of the qualified health claims FDA allows for green tea: Examples of health claim on <a href="http://www.teaforhealth.com">www.teaforhealth.com</a> include the following: “Green tea may reduce the risk of breast and prostate cancers. FDA has concluded that there is credible evidence supporting this claim although the evidence is limited.” Examples of health claim on <a href="http://www.greenteahaus.com">www.greenteahaus.com</a> in the form of headings categorized as “educational materials” include the following: “Epidemiological and clinical studies on the relationship between cancer risk and the consumption of green tea . . .” Examples of health claims in “The Truth in Tea” include the following: • “[H]igh consumption of green tea [is] associated with reduced cancer rates of the breast, esophagus, stomach, colon, rectum, pancreas, urinary bladder, prostate, lung, liver and ovary . . .” • “Recent medical research has provided evidence that drinking green tea may reduce the risk of fatal heart attack, stroke, Alzheimer’s disease, Parkinson’s disease, help reduce body fat and help fight viral infection.”</td>
</tr>
<tr>
<td>Diamond Food, Inc. (Feb. 22, 2010) Diamond of California Shelled Walnuts</td>
<td>“Supportive but not conclusive research shows that eating 1.5 oz of walnuts per day, as part of a low saturated fat and low cholesterol diet, and not resulting in increased caloric intake, may reduce the risk of coronary heart disease. Please refer to nutrition information for fat content and other details about the nutritional profile of walnuts.”</td>
<td>The letter states that the following statement on the product label is an unauthorized health claim: “The omega-3 in walnuts can help you get the proper balance of fatty acids your body needs for promoting and maintaining heart health. In fact, according to FDA, supportive but not conclusive research shows that eating 1.5 oz of walnuts per day, as part of a low saturated fat and low cholesterol diet, and not resulting in increased caloric intake, may reduce the risk of coronary heart disease” The letter further states that the statement suggests that the evidence supporting a relationship between walnuts and coronary heart disease is related to the omega-3 fatty acid content of walnuts. There is not sufficient evidence to identify a biologically active substance in walnuts that reduces the risk of coronary heart disease.</td>
</tr>
</tbody>
</table>

Source: FDA documents.

Note: FDA’s warning letters to both companies also cited violations other than those for qualified health claims; these violations are not shown in the table.

In a March 2010 open letter to industry, the FDA Commissioner noted that the warning letters did not attempt to cover all products with labeling violations, but that they did cover a range of concerns about how false or misleading labels can undermine the “intention of Congress to provide consumers with labeling information that enables consumers to make informed and healthy food choices.” The warning letters gave companies 15 working days from the receipt of the letters to respond with the steps
that they are or will be taking to correct their label violations. According to FDA officials, all the companies responded to the warning letters. When FDA has verified that the violations have been addressed, it will issue, and post to its Web site, closeout letters indicating that corrective actions were taken, according to the officials. As of December 23, 2010, FDA had not issued closeout letters for any of the 17 companies that received these warning letters for labeling violations. (App. V summarizes the other 15 warning letters and an untitled letter that FDA issued regarding claims found on food labels during the December 2009 through February 2010 oversight initiative.)

Research has shown, and stakeholders have indicated, that consumers find it difficult to understand the differences between qualified health claims and health claims with significant scientific agreement. Consumers have similar difficulties understanding the differences among health, structure/function, and other health- and nutrient-related claims. European Union (EU) and Canadian food labeling officials, noting the potential for qualified health claims to confuse or mislead consumers about the benefits of a food, stated that their governments do not allow the use of qualified health claims on food labels.

Consumers Have Difficulty Understanding the Level of Scientific Support for Qualified Health Claims and How These Claims Differ from Other Claims

Research conducted over the past decade by FDA, FTC, and the International Food Information Council on consumers’ understanding of qualified health claims consistently shows that consumers find it difficult to understand the degree of scientific support for qualified health claims on food labels. In particular, according to our analysis of this research, consumers cannot consistently distinguish between health claims, which have significant scientific agreement, and qualified health claims, which have lower levels of scientific evidence (i.e., good/moderate and low levels of scientific support). For example,

---

12The International Food Information Council is a nonprofit, nonpartisan communications organization whose mission is to effectively communicate science-based information about food safety and nutrition to health professionals, government officials, consumers, and others.
• According to a 2009 FDA study, which was based on a Web-based survey of over 7,000 adults, the respondents could not distinguish between the strength of scientific evidence for claims with significant scientific agreement and for claims with good/moderate levels of support.13 Specifically, respondents’ ratings of scientific support for two health claims with substantial scientific support (i.e., the benefits of soluble fiber and of stanol esters from vegetable oil in reducing the risk of heart disease) were not consistently different than ratings for the qualified health claims for omega-3 fatty acids and heart disease, which have good/moderate scientific support.13

• FDA’s 2009 study also found that respondents could not consistently distinguish between the level of support for qualified claims related to (1) omega-3 fatty acids for reducing the risk of heart disease, which has good/moderate scientific support, and (2) monosaturated fat from olive oil for reducing the risk of heart disease, which has a low level of scientific support.

• The International Food Information Council’s 2008 research on consumers’ understanding of qualified health claims, based on a Web-based survey of 5,642 adults, showed that words such as “inconclusive” meant different things to different consumers.15 According to the council, some consumers believed that “inconclusive” implied “honesty” and “believability,” while others believed that it implied extreme negativity. However, the phrase “not conclusive” is used in four qualified health claims, including the walnut claim: “Supportive but not conclusive research shows that eating 1.5 ounces per day of walnuts, as part of a low saturated fat and low cholesterol diet and not resulting in increased caloric intake, may reduce the risk of coronary heart disease.”

13Conrad J. Choinière and Linda Verrill, FDA, Experimental Study of Qualified Health Claims: Consumer Inferences about Monounsaturated Fatty Acids from Olive Oil, EPA and DHA Omega-3 Fatty Acids, and Green Tea (November 2009).

14Stanol esters are a group of chemical compounds that reduce low-density lipoprotein (LDL) cholesterol. They are found naturally occurring in small quantities in fruits, vegetables, nuts, seeds, whole grain, legumes, and vegetable oils, and are added to certain food for their health benefits.

The council’s research also showed that consumers had trouble distinguishing the four distinct levels of scientific support behind claims—that is, distinguishing among the (1) significant scientific agreement for health claims and, for qualified health claims, the (2) moderate scientific evidence, (3) limited or low scientific evidence, and (4) little or extremely low scientific evidence. Regardless of the different language options used, 78 percent of consumers ranked the four levels incorrectly.

FTC’s 2005 study presented the findings of research on consumers’ perceptions of print advertisements containing qualified health claims, obtained from interviews of 480 adults, in eight geographically dispersed shopping mall facilities. According to FTC officials, although it might be possible to communicate the proper order of various levels of qualification using strongly worded language or graphical displays, it would nonetheless be difficult to develop qualifying language in advertising to communicate a low level of scientific certainty. The survey results indicated that none of the tested language, whether appearing in real or fictitious product advertisements, communicated serious limitations in scientific evidence. In addition, consumers interpreted all of the tested advertisements in a disparate fashion. For example, in an advertisement for a fictitious antioxidant vitamin supplement, about two-thirds of the consumers responding either overestimated or underestimated the certainty of the science.

Furthermore, on the basis of its own research as well as FDA’s, FTC has continued to express concern about the potential for qualified health claims to mislead consumers. In 2009, the Director of FTC’s Bureau of Consumer Protection announced that one of the bureau’s primary goals was to prevent claims made in food advertising that were not supported by the weight of the scientific evidence, noting that one outlier study should not be the sole basis of a claim, particularly for a health benefit. According to FTC’s Enforcement Policy Statement of Food Advertising, the commission believes that qualified claims based on evidence that is inconsistent with the larger body of evidence have the potential to mislead consumers and therefore are likely to violate the Federal Trade Commission Act. Further noting that “objective claims carry with them the

---


implication that they are supported by valid evidence,” in its policy statement, FTC recognized that qualified health claims may be permitted in certain limited instances—if they expressly convey “clearly and fully” the extent of scientific support. However, as noted in the statement, if such claims are not consistent with the majority of evidence, they could potentially mislead consumers and, under its legal framework, FTC would find them deceptive.

If consumers cannot properly distinguish among the claims, they may be unable to make informed decisions about the likelihood that a food will have the claimed health benefit. Some consumer and health association stakeholders told us that qualified health claims should be eliminated because of consumers’ confusion, although a few suggested that the claims with moderate scientific support should remain. In addition, in a January 2007 letter to FDA, the American Medical Association stated that it continues to vigorously oppose the use of qualified health claims on foods; that FDA has no basis for allowing them because, according to the association, *Pearson v. Shalala* does not apply to foods; and that recent research has shown that qualifying language cannot remedy the possible deceptiveness of qualified health claims. On the other hand, the Grocery Manufacturers Association supports the continued use of qualified health claims, and according to the association representatives, some members find them to be a useful advertising tool.

In part because of the results of FDA’s research on consumers’ understanding of qualified health claims, the European Union does not allow these claims on food labels, according to EU labeling officials. These officials said that these claims may confuse or mislead consumers. Similarly, Canada does not allow these claims because of their potential to confuse or mislead consumers, according to a Canadian food labeling official.

Research and Stakeholders Find Consumers Have Difficulty Distinguishing among Health, Qualified Health, Structure/Function, and Nutrient Content Claims

According to research conducted by FDA, the International Food Information Council, and academia, consumers have difficulty distinguishing among the many different types of claims on food labels, including health claims, qualified health claims, structure/function claims, and nutrient content claims. For example,

- According to a 2008 article on how 1,077 participants in a 2006 FDA study interpreted health messages on food labels, when respondents were well acquainted with the nutrient or diet-disease relationship—such as the link between calcium and osteoporosis—there was no difference in how
strongly respondents believed in the stated health benefit, regardless of whether the claim was a health, structure/function, or nutrient content claim.\textsuperscript{18}

- According to the International Food Information Council’s 2008 study, consumers rate the level of scientific evidence and other attributes associated with a product containing a structure/function claim as similar to the evidence and other attributes of health claims with significant scientific agreement on a product. Specifically, the council found that consumers are just as likely to purchase a product with a structure/function claim, which FDA does not review, as they are to purchase a product with a health claim supported by significant scientific agreement, which FDA does review. Furthermore, structure/function claims were perhaps the most popular of all the claims the council tested: Most consumers liked their brevity and general health messages more than health claims, which they saw as too wordy and too disease specific. For example, several consumers mentioned that they did not like to see the word “cancer” on the labels for their food products, even if the label asserted the food would help prevent cancer.

- Academic researchers also noted that consumers tend to interpret the lack of disclaimers (statements that FDA has evaluated the claims on certain dietary supplements) as meaning that the claim had received FDA’s review and approval.\textsuperscript{19}

FDA reviews some health- and nutrient-related claims on food, but many are not reviewed (e.g., structure/function claims), and as a result, public health may not be adequately protected, according to a 2010 report by the National Academies’ Institute of Medicine (IOM). According to this IOM report, consumers have difficulty assessing the scientific merits of these claims. Similarly, some health and consumer stakeholders we interviewed said that FDA should particularly review structure/function claims because consumers do not understand the difference between them and health claims that do receive FDA’s review. They also said that like health claims, structure/function claims should have scientific standards to

\textsuperscript{18}Chung-Tung Jordin Lin, FDA “How Do Consumers Interpret Health Messages on Food Labels?” Nutrition Today, Vol. 43., No. 6 (November/December 2008).

\textsuperscript{19}Neal Hooker and Ratapol Teratanavat, “Dissecting Qualified Health Claims: Evidence From Experimental Studies,” Critical Reviews in Food Science and Nutrition, Vol. 48, Iss. 2 (February 2008).
ensure they are not false or misleading and that these claims should not be allowed on foods that are high in sugar, saturated fat, or sodium.

In addition, according to FDA officials, the agency would be better able to take enforcement action against companies that make false or misleading structure/function claims if it had express authority to access company research. Furthermore, a contributing author of the IOM report explained that while FDA can conduct its own studies as resources permit, it needs authority to require food companies to provide studies focused on specific claims and products. Some stakeholders, such as representatives from the American Society for Nutrition and the Center for Science in the Public Interest, said that FDA should have authority to require consumer and scientific studies from industry so that industry, rather than FDA, bears the burden of proof that a claim is truthful and not misleading. However, a representative from the American Dietetic Association expressed concern that giving FDA access to companies’ research could hinder industries’ willingness to conduct research, while a representative from the Grocery Manufacturers Association opposed any suggestions that FDA be given additional authority to require proprietary studies from its members.

Industry More Widely Uses Structure/Function Claims on Food with Minimal FDA Oversight, but FTC Has Taken Some Action When These Claims Were Deceptive

While FDA data indicate that industry’s interest in qualified health claims on food labels has slowed to one petition for such a claim since 2006, data also indicate that industry more widely uses structure/function claims to communicate health benefits to consumers, with minimal FDA oversight. However, FTC has taken action to cause a major food company to withdraw deceptive structure/function claims on its labels and advertising.

Industry More Often Uses Structure/Function Claims on Food with Minimal FDA Oversight

As noted earlier and in table 3, FDA’s FLAPS results found only about 0.4 percent of food labels in grocery stores had qualified health claims. In contrast, about 4.3 percent had health claims, and 5.5 percent had structure/function claims. The most common claims found in the FLAPS study were nutrient content claims or variations of these claims. Consumers can usually check the nutrition facts panels or ingredients lists, which are required on food labels, for corroborating information for
nutrient content claims. Although consumers are able to verify information from nutrient facts panels, they do not have such information readily available on labels for health claims, qualified health claims, or structure/function claims.

Also, the 2009 study by West Virginia University researchers showed that companies that could have used qualified health claims chose more than twice as often to use structure/function claims. This study focused on labels of foods eligible to use qualified health claims. Specifically, it found that only 4.6 percent of food packages eligible for a qualified health claim actually used one, while 9.4 percent of these eligible packages used structure/function claims instead. The study identified possible reasons for choosing structure/function claims more often than qualified health claims; for example, (1) structure/function claims, unlike qualified health claims, do not mention diseases; (2) companies do not want consumers to relate unpleasant or unfavorable associations (such as cancer or colon polyps) with their products; and (3) the qualifying language FDA used in the qualified health claims is more limiting than companies had hoped. In addition, research funded by the food industry has shown that consumers prefer to see shorter, simpler claims on food labels. Also, companies are not required to submit scientific support or obtain FDA's premarket review and approval before using a structure/function claim on a food label.

As we said earlier, FDA is responsible for ensuring the proper labeling of food, and the use of structure/function claims is subject to the general statutory requirement that labeling not be false or misleading. However, FDA has not given companies guidance on the scientific support needed to prevent false or misleading information in a structure/function claim for food. FDA has guidance for the dietary supplements industry on the scientific support needed to prevent false or misleading information for a structure/function claim for dietary supplements. In technical comments, FTC staff stated that “FDA could issue a statement that the same principles apply to foods.”


One way for FDA to identify potentially false or misleading structure/function claims would be by including an examination of these claims in food facility compliance inspections. Following the *Compliance Program Guidance Manual*, inspectors are instructed to examine any three food labels from a facility. Inspectors are to focus their label reviews on violations, such as failure to declare allergens and failure to provide nutrition information. For nutrient content claims on food labels, inspectors can check the facts panels and ingredients lists to help corroborate the claims. Their inspection guidance manual identifies the statutes and regulations for health claims and nutrient content claims but does not provide instructions for identifying potentially false or misleading structure/function claims for food.

If FDA determines that a structure/function claim is false or misleading, it may send a warning letter to the company. Although FDA officials could not identify any warning letters or enforcement actions for such violations on food labels, they provided two warning letters issued in 2001 for nutrient content claim violations, in which FDA also expressed concerns with structure/function claims made by the companies on their food labels. Specifically, those warning letters mentioned the following structure/function claim concerns:

- One warning letter, for New Morning Organic Ginseng Crunch and Organic Ginkgos, noted the label claims “for mental concentration, physical vitality and energy and its . . . anti-oxidant qualities” and “to sustain memory.” According to FDA's warning letter, the foods were represented as cereals. The letter noted that the claimed effect must be achieved through the nutritive value of a food, and that otherwise the product would be considered a drug under the Federal Food, Drug, and Cosmetic Act, and therefore subject to FDA's drug regulations.

- The second warning letter, for Hansen's Healthy Start Immune Juice, had a label claim stating that “Echinacea . . . may help stimulate the body’s production of interferon.” FDA again stated that the claimed effect had to be achieved through the nutritive value of the food and that otherwise the product would be considered a drug under the Federal Food, Drug, and Cosmetic Act, and therefore subject to FDA's drug regulations.

---

22FDA informed us that its data system for tracking warning letters could not be searched for structure/function claims on food. FDA officials were able to identify only the two letters discussed herein.
FDA officials told us that these warning letters were issued about 16 months after an FDA-sponsored stakeholder meeting in 2000, which was convened to seek input for what FDA viewed at the time as a need for immediate attention to the growing use of structure/function claims and the serious oversight dilemma they posed for FDA. At the meeting, the stakeholders—from FDA, industry, consumer groups, and academia—identified an urgent need for regulating and overseeing structure/function claims and noted that FDA could not wait for legislative changes. The stakeholders stated, among other things, that

- consumers cannot be confident that the claims are truthful and not misleading because their scientific support is unclear,
- some consumers lack the tools or understanding needed to evaluate claim messages and understand what they mean, and
- consumers cannot clearly distinguish among health claims, structure/function claims, and other claims.

In a January 2001 “Letter to Manufacturers,” FDA reminded food companies that, among other things, “the claimed structure/function effects for foods must be achieved through nutritive value. If [they are] not, the product is subject to regulation as a drug.”

Subsequently, in a 2006 Federal Register notice, FDA requested comments on a series of questions on, among other things, whether it should require companies to notify FDA within 30 days before marketing a food with a structure/function claim, and whether FDA should require a disclaimer stating that FDA had not reviewed or approved the claim. As we noted earlier, federal law requires such notification and a disclaimer on dietary supplements for all structure/function claims that reads, “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” In commenting on these issues, two consumer groups supported requiring companies to submit structure/function claims for foods with novel ingredients (e.g., ingredients that are added to and not normally found in the food) to FDA for premarket approval. One of the consumer groups noted that disclaimers for dietary supplements have been shown to be ineffective, and thus the group was not suggesting they be used on food. A few industry groups commented that they believed FDA lacked authority to require a disclaimer or premarket approval. FDA has not adopted a disclaimer or notification requirement for structure/function claims on food labels.
Unlike FTC, which may require companies to provide the evidence to support their advertising claims, FDA bears the burden of proving that a structure/function claim is false or misleading without having the authority to compel companies at the investigation stage to produce the evidence that the companies assert as support for their advertising claims. According to senior attorneys in FDA’s Office of the Chief Counsel, FDA’s efforts to meet that burden are hampered by the lack of access to the evidence that a company relies on to make such a claim. In particular, while FDA may ask a company to provide its evidence, FDA does not have express legal authority to compel the company to provide information. To support an action, FDA may need to review the scientific literature to determine whether the literature supports a claim—an effort that may be time consuming and labor intensive. FDA may also need to establish through research how consumers perceive the claim. If the structure/function claim, or any claim for that matter, is one for which there is little publicly available information, it can be difficult for FDA to develop the evidence needed to support an enforcement action. It also can be difficult to evaluate the support for a structure/function claim when the functions, such as “immunity” or “attention,” do not have generally established measures for the claimed benefit. For example, it is not necessarily clear what outcome measures would be a valid means of assessing whether a food “improves vitality.”

Furthermore, in contrast to the United States, the EU follows a different course: EU Commission officials told us the responsible EU food agency must preapprove the type of food claims that FDA calls structure/function claims before they can be used. EU Commission officials also stated that their scientific review agency rejected 85 percent of structure/function claims companies have submitted because of the lack of scientific support. Canada is also reviewing structure/function claims food companies have submitted by developing a list of approved claims; it too has rejected most claims, including some found on labels in the United States, according to a Canadian official. To protect the public from false or misleading claims, the Canadian food labeling agency is working with the Canadian agency that regulates advertising to develop a framework for regulating structure/function claims.
Although FTC, operating under its memorandum of understanding with FDA, has not historically focused on claims on food labels, it has recently emphasized that health claims on food must be adequately substantiated and presented in a manner that is truthful and not deceptive, according to FTC officials. To clarify how its authority related to FDA’s labeling regulatory scheme under NLEA, FTC issued an Enforcement Policy Statement on Food Advertising in May 1994 that provided the legal framework for its related enforcement actions. Under that framework, FTC would find an advertisement deceptive and therefore unlawful, if

- the advertisement contained a representation or omission of a material fact that is likely to mislead consumers acting reasonably under the circumstances, or

- the advertiser did not possess and rely on reasonable substantiating evidence of the claim’s truth.

FTC has filed complaints on claims made in food advertising that it alleged to violate the Federal Trade Commission Act, and taken enforcement actions for alleged false structure/function claims on food labels and in advertisements. Specifically, in 2009, FTC reached a settlement with Kellogg on a complaint alleging that the company made unsubstantiated claims that Frosted Mini-Wheats was “clinically shown to improve kids’ attentiveness by nearly 20 percent.” The company agreed to refrain from making comparable claims. In 2010, FTC reopened the complaint based on claims made by Kellogg that Rice Krispies cereal “now helps support your child’s immunity.” To resolve the investigation into the new claims, Kellogg agreed to new advertising restrictions and a revised settlement order.

FTC officials told us the commission could not have taken the actions that it did without authorities, such as access to companies’ proprietary market and scientific research. They said FTC needed research and documentation from Kellogg to determine whether the information supported an enforcement action. FTC has authority to compel companies to provide evidentiary documents, among other things, and therefore it can get such documents on a voluntary basis. FTC obtained Kellogg’s documents showing that the attentiveness claim was allegedly

23FTC does not use the term “structure/function claim,” but FDA confirmed that the claim met its understanding of a structure/function claim.
false. According to the FTC complaint, Kellogg’s research showed that the cereal increased children’s attentiveness by only about 11 percent.

FTC officials told us that they had informed FDA about their actions concerning Kellogg. However, because Kellogg cooperated, the two agencies did not have to coordinate further. Since September 2009, through monthly working group meetings, FDA and FTC have been coordinating to, among other things, prevent duplication of effort and share information on cases of mutual interest.

Conclusions

Initially in 2002, FDA thought it would receive a flood of petitions for qualified health claims from food companies. However, this demand never materialized, and in fact, FDA has received only 16 petitions with 60 proposed claims and only 1 petition since 2006. Furthermore, the 12 qualified health claims that FDA has allowed are being minimally used by food companies. Structure/function claims are another matter, making up more than 5 percent of all food labels. FDA recognized a decade ago the growing use of such claims and the serious oversight dilemma they pose. Unlike FTC, which can require companies to provide the evidence to support their food advertising claims, FDA bears the burden of proving that a structure/function or other type of claim is false or misleading. Our work indicates that FDA’s efforts to meet that burden are hampered by the lack of access to the scientific support that a company relies on to make such a claim. In particular, while FDA may ask a company to provide its support, FDA does not have express legal authority to compel the company to provide it. FTC, on the other hand, has authority to compel companies to provide evidentiary documents.

Furthermore, FDA has not given companies guidance on the level of scientific evidence needed to prevent false or misleading information in a structure/function claim for food; by not providing such guidance, FDA may not be doing all it can to help ensure that food labels are free from false or misleading claims. Moreover, FDA has not given its inspectors instructions in the *Compliance Program Guidance Manual* for identifying potentially false or misleading information in structure/function claims when examining food labels as part of food facility compliance inspections; without such instructions, inspectors may be missing one way for FDA to identify potentially false or misleading structure/function claims.
Recommendations for Executive Action

To ensure that the health-related claims on food labels are not false or misleading to consumers, we recommend that the Secretary of Health and Human Services direct the Commissioner of FDA to take the following three actions:

- identify and request from Congress the authorities needed to access evidence from food companies regarding potentially false or misleading structure/function or other claims on food that would allow the agency to establish whether there is scientific support for the claims;

- provide guidance to industry on the type and strength of scientific evidence needed to prevent false or misleading information in a structure/function claim; and

- amend the *Compliance Program Guidance Manual* instructions to FDA inspectors for reviewing food labels during inspections of food facilities, to include steps for identifying potentially false or misleading structure/function claims for further review.

Agency Comments and Our Response

We provided a draft of this report to the Secretary of Health and Human Services and FTC’s General Counsel for their review and comment. In written comments, the Department of Health and Human Services’ (HHS) Assistant Secretary for Legislation stated that FDA welcomed the report for calling attention to the extremely complex and challenging legal and regulatory environment under which FDA works to protect consumers from false and misleading label claims on foods, particularly qualified health claims and structure/function claims. HHS stated that FDA also welcomed the report for calling attention to the differences in the legal authorities between FDA and FTC that allow FTC to compel companies to provide evidence supporting their advertising claims. FTC staff provided technical comments that we incorporated in the report, as appropriate.

With regard to our recommendations, HHS indicated that FDA generally agreed with our first two recommendations but believes that our third recommendation is impractical. Specifically, regarding our first recommendation—to identify and request from Congress the authorities needed to access evidence from food companies regarding potentially false or misleading structure/function or other claims on food that would allow the agency to establish whether there is scientific support for the claims—HHS commented that FDA would work to determine better approaches to enhancing its oversight of structure/function claims, including whether additional statutory authorities are needed.
Regarding our second recommendation—to provide guidance to industry on the type and strength of scientific evidence needed to prevent false or misleading information in a structure/function claim—HHS noted FDA’s support for providing guidance to industry on the type of evidence needed. FDA agreed to consider developing such guidance as agency priorities and resources permit. FDA has guidance for the dietary supplements industry on the scientific support needed to prevent false or misleading information for a structure/function claim for dietary supplements. As we noted earlier, in technical comments, FTC staff stated that “FDA could issue a statement that the same principles apply to foods.”

Regarding our third recommendation—to amend the Compliance Program Guidance Manual instructions to FDA inspectors for reviewing food labels to include steps for identifying potentially false or misleading structure/function claims during inspections of food facilities—FDA agreed that field investigators, to whom the Compliance Program Guidance Manual is targeted, have significant exposure to food labels that may contain any one of a myriad of structure/function claims during their routine inspections of food producers. However, the agency sees significant challenges to providing specific steps to investigators to identify potentially false or misleading structure/function claims during inspections. FDA found the recommendation impractical, noting that judging whether a structure/function claim is false or misleading requires knowledge of the science that would support or dispute the claim. FDA believes it would be impossible to provide inspectors with the knowledge necessary to make such an assessment in the field. FDA further states that, while structure/function claims are not highlighted as an area of emphasis, the Compliance Program Guidance Manual includes instructions for inspectors to collect information to determine the extent to which food products are in compliance with all labeling requirements and provides additional references regarding the types of claims permitted on food labels. We agree that the guidance manual includes several instructions to help inspectors review food labeling. It contains, for example, the requirements for the nutrition facts panel and identifies allergens that must be declared. The guidance manual also identifies the statute and regulations for health claims and nutrient content claims, as well as the statute and regulations prohibiting food labeling that is false or misleading. However, the Compliance Program Guidance Manual does not provide instructions to help inspectors identify potentially false or misleading structure/function claims on food. While we agree it may be impractical for field inspectors to judge whether a claim is false or misleading, we believe that FDA can amend the instructions for inspectors with steps to help them identify potentially false or misleading
structure/function claims that may warrant further FDA review—leaving the determinations of whether the claims are indeed potentially false or misleading to FDA staff with the necessary science backgrounds. We clarified our recommendation. HHS's written comments appear in appendix VI.

FDA also provided technical comments that we incorporated in the report, as appropriate.

We are sending copies of this report to the appropriate congressional committees, the Secretary of Health and Human Services, the Commissioner of FDA, the Federal Trade Commission, and other interested parties. In addition, the report will be available at no charge on GAO's Web site at http://www.gao.gov.

If you or your staff have any questions about this report, please contact me at (202) 512-3841 or shamesl@gao.gov. Contact points for our Offices of Congressional Relations and Public Affairs may be found on the last page of this report. Key contributors to this report are listed in appendix VII.

Lisa Shames
Director, Natural Resources and Environment
In 2008 we reported on the Food and Drug Administration’s (FDA) efforts to help consumers choose healthy foods through the information provided on food labels. In that report we presented information on FDA’s administration of health claims, and specifically its treatment of qualified health claims, after the Pearson v. Shalala ruling. That information is repeated here with some modifications.

As we reported, the Nutrition Labeling and Education Act of 1990 (NLEA) amended the Federal Food, Drug, and Cosmetic Act to include provisions that govern the use of health claims on food labeling. For conventional foods, the NLEA requires that any claim that expressly or by implication characterizes the relationship of a nutrient to a disease or health-related condition must be authorized by the Secretary of Health and Human Services (delegated to FDA) through a regulation. Under the NLEA, FDA may authorize a health claim for a conventional food if it determines, based on the totality of publicly available scientific evidence, that there is "significant scientific agreement" among experts—qualified by scientific training and experience to evaluate such claims—that the claim is supported by such evidence. Although the NLEA also provided for the use of health claims in dietary supplement labeling, Congress did not require health claims for dietary supplements to be subject to the same statutory procedures and standards as health claims for conventional food. Instead, health claims for dietary supplements were to be subject to procedures and standards established in regulations issued by the Secretary of Health and Human Services (delegated to FDA).

In 1991, FDA published a proposed rule in the Federal Register, proposing the implementation of statutory procedures and standards for health claims for conventional food, and proposing to adopt those same procedures and standards for dietary supplement health claims.

---

4. In addition, a claim may be authorized if a relevant scientific body of the federal government or the National Academies, or a subdivision thereof, has published an authoritative statement, currently in effect, about the relationship between a nutrient and a disease or health-related condition to which the claim refers.
However, before the rule could be finalized, Congress passed legislation that generally prohibited FDA from implementing the NLEA for dietary supplements until December 15, 1993. Therefore, in January 1993, when FDA adopted the final rules for health claims for conventional foods, it did not finalize rules for health claims on dietary supplements. However, 1 year later, after the prohibition of implementation of NLEA for dietary supplements had expired, FDA adopted a rule that subjected health claims for dietary supplements to the same general requirements that applied to conventional foods. Under those rules, any person wanting to include a health claim on the label for a conventional food or dietary supplement must petition FDA for authorization before including the claim on the label. If FDA determines, based on the totality of publicly available information, that there is significant scientific agreement in support of that claim, it will authorize its use in regulation.

FDA’s health claim regulations for dietary supplements were the subject of several lawsuits in the 1990s. In a case known as Pearson v. Shalala, the U.S. Court of Appeals for the District of Columbia Circuit held that the First Amendment does not permit FDA to prohibit a potentially misleading health claim on the label of a dietary supplement, unless FDA considers whether a disclaimer on the product’s label could negate the potentially misleading nature of that claim. Specifically, the court stated that although inherently or actually misleading information in food labeling or advertising may be prohibited, potentially misleading information cannot face an absolute prohibition. Instead, potentially misleading information may be regulated only if those regulations directly advance a substantial government interest and offer a reasonable fit between the government’s goals and the means chosen to accomplish those goals. The court found a substantial interest in protecting the public health and preventing consumer fraud. However, it found that FDA’s regulation requiring health claims to be supported by significant scientific agreement did not directly advance the interest in public health, and even though the regulations directly advanced the interest in preventing consumer fraud, the fit

---

9164 F.3d 650 (D.C. Cir. 1999).
between the goals of the regulations and the means employed—an outright ban without the possibility of a disclaimer—was not reasonable.10

Following the decision in *Pearson v. Shalala*, FDA announced its plan to respond, stating that it would deny, without prejudice, all petitions for the use of health claims on dietary supplements that did not meet the significant scientific agreement standard while the agency conducted and completed a rulemaking to consider the procedures and standards governing such claims. Then, according to FDA, once a rule was finalized, the agency would revisit the petitions it had denied. However, in 2000, citing concerns over additional First Amendment challenges, FDA announced plans to modify that policy.11 FDA stated that it would continue to approve health claims for dietary supplements that met the significant scientific agreement standard, but it would exercise its enforcement discretion and not take action against health claims for dietary supplements that failed to meet the standard under certain circumstances. Specifically, upon the submission of a valid petition for preapproval of a health claim for a dietary supplement, if FDA did not find significant scientific agreement, but, in evaluating the weight of the evidence, did find that the scientific evidence in support of the claim outweighed the scientific evidence against it, and consumer health and safety were not threatened, the agency would inform the petitioner of conditions under which the agency would refrain from taking enforcement action against the health claim. If the scientific evidence against the health claim outweighed the scientific evidence in support of it, FDA would deny any use of the health claim.

In 2002, the agency announced the availability of guidance, updating its approach to implementing the decision in *Pearson v. Shalala*.12 In large part, the procedures remained the same; however, FDA included health claims for conventional foods under the procedures, even though *Pearson v. Shalala* directly addressed only dietary supplements. FDA stated that it believed that such a move would precipitate greater communication in

10 In addition, the court found that the Administrative Procedure Act requires that FDA give some “definitional content to the phrase ‘significant scientific agreement,’” either in regulation or on a case-by-case basis so that the regulated class can “perceive the principles which are guiding agency action.” 164 F.3d at 661. FDA subsequently provided guidance describing the meaning of the phrase.


food labeling and thereby enhance public health. In addition, FDA stated that including health claims for conventional foods in its enforcement discretion policy would help avoid further constitutional challenges. In 2003, FDA announced the availability of two new guidance documents describing interim procedures that, among other things, addressed a then recent U.S. District Court for the District of Columbia decision that found the weight of the evidence standard that FDA first articulated in guidance in 2000 was inappropriate. According to the district court in that case, FDA should evaluate qualified health claims based on the presence of "credible evidence," not the weight of the evidence. The 2003 guidance documents set forth new procedures for qualified health claims for conventional foods and dietary supplements. Specifically, qualified health claim petitions would be evaluated using an evidence-based ranking system that would rate the strength of the publicly available scientific evidence. A claim would be denied if there was no credible evidence to support it. Otherwise, based on the competent and reliable scientific evidence in support, a claim would be assigned to one of four ranked levels—the first level being "significant scientific agreement among qualified experts" and the remaining three levels being for claims supported by some lower level of credible evidence. Each of the three categories not ranked as supported by significant scientific agreement would correspond to one of three standardized qualifying statements (i.e., disclaimers). So long as the qualified health claim bore the appropriate language, met other applicable health claim regulations, and adhered to criteria established in FDA’s letter of enforcement discretion in response to the petition, FDA would exercise its enforcement discretion and refrain from acting against the health claim.

In November 2003, FDA published an Advance Notice of Proposed Rulemaking recognizing the need to establish transparent, long-term

---


15 Those qualifying statements being (1) "although there is scientific evidence supporting the claim, the evidence is not conclusive"; (2) "some scientific evidence suggests . . . however, FDA has determined that this evidence is limited and not conclusive"; and (3) "very little and preliminary scientific research suggests . . . FDA concludes that there is little scientific evidence supporting this claim." FDA, Interim Procedures for Qualified Health Claims in the Labeling of Conventional Human Foods and Human Dietary Supplements (July 10, 2003).
procedures that have the effect of law. In that announcement, FDA presented several regulatory alternatives it might take, stating that it could (1) incorporate the interim procedures and evidence-based ranking system the agency described in its 2000 guidance into regulation; (2) subject health claims to notice-and-comment rulemaking, as before Pearson v. Shalala, but reinterpret the “significant scientific agreement” standard to refer to the evidence supporting the claim being made, instead of the underlying substance-disease relationship; or (3) treat qualified health claims as outside the NLEA and regulate them on a postmarket basis (i.e., pursue the product as misbranded if the health claim renders the label false or misleading because the claim lacks substantiation). FDA did not work on this proposed rulemaking in 2010.

FDA issued final guidance describing the evidence-based review system it intends to use to evaluate publicly available scientific evidence for health claims and qualified health claims in January 2009. This guidance replaced the 2003 guidance document describing the evidence-based ranking system. The 2009 guidance document set out an approach that FDA intends to use to evaluate the results of studies from which scientific conclusions can be drawn and rate the strength of the total body of publicly available evidence.

In a 2010 case before the U.S. District Court for the District of Columbia, a dietary supplement manufacturer challenged FDA’s decisions regarding specific health claims. At issue in this case were five proposed health claims describing a purported relationship between selenium and the risk of cancer. FDA had denied four of the claims outright, and it stated that it would exercise enforcement discretion regarding a modified version of the remaining claim. The manufacturer challenged the denial of the four claims and the modified claim, describing the modified claim as an imposition of an onerous, value-laden set of qualifications and as unreasonably long and burdensome for industry to include. The court

---

20 714 F. Supp. 2d at 58.
examined FDA's review of the scientific evidence, referencing procedures laid out in the agency’s 2009 guidance document. The court questioned a number of FDA’s conclusions and remanded the denied claims to the agency to reevaluate.\textsuperscript{21} In addition, the court found FDA’s modified disclaimer at odds with the First Amendment. The court stated that “FDA is obligated to at least consider the possibility of approving [the manufacturer’s] proposed language with the addition of [a] ‘short, succinct, and accurate disclaimer['].’”\textsuperscript{22}

\textsuperscript{21}The court directed FDA reevaluate one of the claims and draft one or more disclaimers. For the remaining three denied claims, the court directed FDA to either draft disclaimers to accompany the manufacturer’s claims, or set forth the empirical evidence that any disclaimer would fail to correct the claims’ purported misleading effects. 714 F. Supp. 2d at 72.

\textsuperscript{22}714 F. Supp. 2d at 71 (quoting \textit{Pearson v. Shalala}).
We examined (1) the results of FDA’s efforts to allow the use of qualified health claims on food, and its oversight of these claims and (2) what is known about consumers’ understanding of qualified health claims on food. In addition, we examined industry’s use of structure/function claims on food and FDA’s oversight of these claims.

To examine the results of FDA’s efforts to allow food companies to use qualified health claims on food, we assessed FDA data and documentation, including health claim guidance and petitions from industry. We reviewed petitions for qualified health claims and FDA’s letters to petitioners stating that if a company used the submitted claim as modified by FDA, the agency would exercise its enforcement discretion and not take action against the claim. We also requested data on FDA resources devoted to qualified health claims and petitions. Although FDA does not maintain data on expenditures and staff charges that would allow it to provide the actual amount it expended on qualified health claims since 2000, FDA estimated that its Center for Food Safety and Applied Nutrition (CFSAN) expended at least $12.8 million since 2000, including the expenses associated with about 88.7 full-time equivalent staff, to administer health and qualified health claim activities for food labeling. This estimate does not represent FDA’s total expenditures on activities related to health claims and qualified health claims for the period because FDA officials could not provide estimates or actual data on expenditures and staff years for other than CFSAN with any degree of confidence.

We reviewed the literature to identify the extent to which different health- and nutrient-related claims are used on food labels in grocery stores and interviewed industry associations and others regarding the marketing advantages and disadvantages of using qualified health and structure/function claims. We obtained data from articles by FDA and West Virginia University researchers to determine the use of qualified health and structure/function claims on food labels. We assessed the quality of the studies on which the articles were based and found them to be of sufficient quality for the purposes of this review.

To examine FDA’s oversight of qualified health claims, we reviewed FDA guidance and related documents on inspection and enforcement of food labeling claims. We also reviewed those warning letters and enforcement actions that FDA officials were able to identify having taken in response to violations, since 2001, as well as the results of its January 2010 initiative to target oversight of labeling compliance. We assessed the reliability of FDA's data on petitions and health claims by (1) reviewing available information about the data and the system that produced them, (2)
interviewing agency officials knowledgeable about the data, and (3) comparing the results with other sources of data for reasonableness. When we found inconsistencies in the data, we discussed them with agency officials and worked with them to correct the inconsistencies. We determined the data were sufficiently reliable for the purposes of this review.

To examine what is known about consumers’ understanding of qualified health claims on conventional food labels, we conducted a literature search of various databases, such as PubMed, MEDLINE, and ProQuest, to identify relevant research studies; we also asked stakeholders we interviewed to recommend studies. Our selection criteria were that the studies be based on original research on consumers’ understanding of qualified health claims and be less than 10 years old. We identified six research studies, conducted by FDA, the Federal Trade Commission (FTC), the International Food Information Council, and academia, that met these criteria. In addition, FDA and the International Food Information Council identified research studies they had conducted that also addressed consumers’ understanding of other types of claims on food labels, including structure/function claims. These were the aforementioned International Food Information Council study and an additional FDA study. Two GAO social science analysts reviewed, assessed, and agreed on the quality of each of the studies we used and found that, while all the studies had some limitations, the limitations were not so great as to preclude the studies’ use.

We identified stakeholders from health, consumer, and industry groups, as well as researchers, to represent the views of different sectors with regard to consumer perceptions and policy options related to qualified health claims and structure/function claims. We asked FDA and the National Academies’ Institute of Medicine to comment on the list of stakeholders we developed to ensure fairness and balance. The final list included the following:

- **health associations**: the American Heart Association, American Dietetic Association, American Medical Association, and the American Society for Nutrition;

- **consumer groups**: the Consumer Federation of America and the Center for Science in the Public Interest;

- **an industry association**: the Grocery Manufacturers Association; and
Appendix II: Objectives, Scope, and Methodology

• researchers: the International Food Information Council; FTC; FDA; and Neal Hooker, Chair of Food Marketing, St. Joseph’s University, Philadelphia, Pennsylvania.

We also interviewed food labeling officials at agencies from the two largest exporters of agricultural products to the United States—Canada and the European Union—to determine how these trading partners regulated qualified health and structure/function claims.

To examine industry’s use of structure/function claims and FDA’s oversight of these claims, we reviewed studies by FDA and researchers at West Virginia University and discussed the results with FDA compliance officials. We also obtained copies of FDA’s warning letters and discussed those and FDA oversight activities. We met with FTC officials and compared and contrasted FDA’s and FTC’s responsibilities and authorities with respect to food labeling and advertising claims, and examined actions taken by FTC against a company for deceptive structure/function claims. We also met with FTC officials to discuss the commission’s interactions with FDA on overseeing the proper use of claims on food labeling and advertising.

We conducted this performance audit from January 2010 through December 2010 in accordance with generally accepted government auditing standards. Those standards required that we plan and perform the audit to obtain sufficient, appropriate evidence to provide a reasonable basis for our findings and conclusions based on our audit objectives. We believe that the evidence obtained provides a reasonable basis for our findings and conclusions based on our audit objectives.
FDA recognizes several types claims that are used on food labels, including the following.

**Health Claims**
- *Health claims* may be authorized by FDA when it determines that there is significant scientific agreement among qualified experts that a totality of publicly available scientific evidence supports the claim, as provided under the Nutrition Labeling and Education Act of 1990. For example, “Diets low in sodium may reduce the risk of high blood pressure, a disease associated with many factors” is one such health claim.

- *Health claims* may also be based on an authoritative statement of a scientific body of the U.S. government or the National Academy of Sciences, as provided under the Food and Drug Administration Modernization Act of 1997;¹ such claims may be used 120 days after notification to FDA. One such claim states: “Diets rich in whole grain foods and other plant foods and low in total fat, saturated fat, and cholesterol may reduce the risk of heart disease and some cancers.”

- *Qualified health claims* are health claims to which FDA has added qualifying language to characterize the strength and limitations of the scientific evidence in support of the claim’s potentially misleading nature, as described in FDA’s 2003 *Consumer Health Information for Better Nutrition Initiative* guidance. One such claim states: “Very limited and preliminary scientific research suggests that eating one-half to one cup of tomatoes and/or tomato sauce a week may reduce the risk of prostate cancer. FDA concludes that there is little scientific evidence supporting this claim.”

**Structure/Function Claims**  
*Structure/function claims* describe the role of a nutrient to affect a bodily structure (e.g., bones) or bodily function (e.g., digestion), or characterize the mechanism by which a nutrient acts to maintain such structure or function. For example, “Calcium helps build strong bones.” FDA is not required by statute to and does not review or approve these claims.

Appendix III: Types of Claims FDA Recognizes, and Industry May Use, on Food

Nutrient Content Claims

- **Nutrient content claims** characterize the level of a nutrient in a food using terms such as “free,” “high,” and “low” (e.g., “high in vitamin C”), or compare the level of a nutrient in a food with that of another food, using terms such as “more,” “reduced,” and “lite,” (e.g., “contains 10 percent more of the Daily Value for fiber than white bread,” “reduced fat—50 percent less fat than our regular brownies,” or “lite cheese cake, 1/3 fewer calories and 50 percent less fat than our regular cheesecake”), as provided under the Nutrition Labeling and Education Act of 1990.

- **Nutrient content claims** may be based on an authoritative statement of a scientific body of the U.S. government or the National Academy of Sciences, as provided under the Food and Drug Administration Modernization Act of 1997. One such claim is “good source of choline,” which must reference the amount or percentage of the daily value of choline in each serving. (Choline is an essential nutrient usually grouped within the B-complex vitamins.)

Implied Nutrient Content Claims

- Claims about a food or ingredient that suggest that the nutrient is absent or present in a certain amount or claims about a food that suggest a food may be useful in maintaining healthy dietary practices and that are made with an explicit claim (e.g., “healthy, contains 3 grams of fat”) are implied claims.

- Claims that a food contains or is made with an ingredient that is known to contain a particular nutrient may be made if the product is “low” in or a “good source” of the nutrient associated with the claim (e.g., “good source of oat bran”).

- Equivalence claims—“contains as much [nutrient] as a [food]”—may be made if both reference food and labeled food are a “good source” of a nutrient on a per serving basis (e.g., “contains as much vitamin C as an 8 ounce glass of orange juice”).

The following label statements are generally not considered implied claims unless they are made in a nutrition context: (1) avoidance claims for religious, food intolerance, or other non-nutrition-related reasons (e.g., “100% milk free”); (2) statements about non-nutritive substances (e.g., “no artificial colors”); (3) added value statements (e.g., “made with real butter”); (4) statements of identity (e.g., “corn oil” or “corn oil margarine”); and (5) special dietary statements made in compliance with a specific provision of Part 105 of Title 21 of the Code of Federal Regulations.
Appendix IV: Health Claims That May Be Used On Food Labels

Table 5 provides information, including sample claim language, on the 12 health claims authorized for foods that meet certain requirements that are based on FDA’s determination that there is significant scientific agreement among qualified experts that all publicly available scientific evidence supports the claims. Table 6 provides information, including the required wording, on the 5 health claims for food that are based on an authoritative statement of scientific body of the U.S. government or the National Academy of Sciences.

<table>
<thead>
<tr>
<th>Food/disease risk</th>
<th>Claim requirements</th>
<th>Model claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium/osteoporosis</td>
<td>The claim must</td>
<td>Calcium and osteoporosis health claim:</td>
</tr>
<tr>
<td></td>
<td>“make clear that adequate calcium or calcium and vitamin D intake throughout life in a healthful diet are essential to reducing osteoporosis risk.”</td>
<td>“Adequate calcium throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis” or “Adequate calcium as part of a healthful diet, along with physical activity, may reduce the risk of osteoporosis in later life.”</td>
</tr>
<tr>
<td></td>
<td>“not imply that adequate calcium or adequate calcium and vitamin D intake is the only recognized risk factor for the development of osteoporosis.”</td>
<td>Calcium, vitamin D, and osteoporosis:</td>
</tr>
<tr>
<td></td>
<td>“not attribute any reduction in risk of osteoporosis to maintaining an adequate dietary calcium or dietary calcium and vitamin D intake throughout life.”</td>
<td>“Adequate calcium and vitamin D throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis” or “Adequate calcium and vitamin D throughout life, along with physical activity, may reduce the risk of osteoporosis in later life.”</td>
</tr>
<tr>
<td>Sodium/hypertension</td>
<td>Required terms:</td>
<td>Diets low in sodium may reduce the risk of high blood pressure, a disease associated with many factors.</td>
</tr>
<tr>
<td></td>
<td>“Sodium,” “high blood pressure.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Includes physician statement (Individuals with high blood pressure should consult their physicians) if claim defines high or normal blood pressure</td>
<td></td>
</tr>
<tr>
<td>Dietary lipids/cancer</td>
<td>Required terms:</td>
<td>Development of cancer depends on many factors. A diet low in total fat may reduce the risk of some cancers.</td>
</tr>
<tr>
<td></td>
<td>“Total fat” or “fat.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>“Some types of cancers” or “some cancers.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Does not specify types of fats or fatty acids that may be related to risk of cancer.</td>
<td></td>
</tr>
<tr>
<td>Dietary saturated fat and cholesterol/coronary heart disease</td>
<td>Required terms:</td>
<td>While many factors affect heart disease, diets low in saturated fat and cholesterol may reduce the risk of this disease.</td>
</tr>
<tr>
<td></td>
<td>“Coronary heart disease” or “heart disease.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Includes physician statement (individuals with elevated blood total—or LDL—cholesterol should consult their physicians) if claim defines high or normal blood total—and LDL—cholesterol.</td>
<td></td>
</tr>
</tbody>
</table>
## Appendix IV: Health Claims That May Be Used On Food Labels

<table>
<thead>
<tr>
<th>Food/disease risk</th>
<th>Claim requirements</th>
<th>Model claim</th>
</tr>
</thead>
</table>
| **Fiber-containing grain products, fruits, and vegetables/cancer** | **Required terms:**  
| “Fiber,” “dietary fiber,” or “total dietary fiber.”  
| “Some types of cancer” or “some cancers.”  
| Does not specify types of dietary fiber that may be related to risk of cancer. | Low-fat diets rich in fiber-containing grain products, fruits, and vegetables may reduce the risk of some types of cancer, a disease associated with many factors. |
| **Fruits, vegetables and grain products that contain fiber, particularly soluble fiber/coronary heart disease** | **Required terms:**  
| “Fiber,” “dietary fiber,” “some types of dietary fiber,” “some dietary fibers,” or “some fibers.”  
| “Saturated fat” and “cholesterol.”  
| “Heart disease” or “coronary heart disease.”  
| Includes physician statement (“Individuals with elevated blood total—or LDL—cholesterol should consult their physicians”) if claim defines high or normal blood total—and LDL—cholesterol. | Diets low in saturated fat and cholesterol and rich in fruits, vegetables, and grain products that contain some types of dietary fiber, particularly soluble fiber, may reduce the risk of heart disease, a disease associated with many factors. |
| **Fruits and vegetables/cancer** | **Required terms:**  
| “Fiber,” “dietary fiber,” or “total dietary fiber.”  
| “Total fat” or “fat.”  
| “Some types of cancer” or “some cancers.”  
| Characterizes fruits and vegetables as “Foods that are low in fat and may contain vitamin A, vitamin C, and dietary fiber.”  
| Characterizes specific food as a “good source” of one or more of the following: dietary fiber, vitamin A, or vitamin C.  
| Does not specify types of fats or fatty acids or types of dietary fiber that may be related to risk of cancer. | Low-fat diets rich in fruits and vegetables (foods that are low in fat and may contain dietary fiber, vitamin A, or vitamin C) may reduce the risk of some types of cancer, a disease associated with many factors. Broccoli is high in vitamins A and C, and it is a good source of dietary fiber. |
| **Folate/neural tube defects** | **Required terms:**  
| Terms that specify the relationship (e.g., women who are capable of becoming pregnant and who consume adequate amounts of folate) “folate,” “folic acid,” “folacin,” “folate, a B vitamin,” “folic acid, a B vitamin,” “folacin, a B vitamin,” “neural tube defects,” “birth defects, spinal bifida, or anencephaly,” “birth defects of the brain or spinal cord—anencephaly or spinal bifida,” “spinal bifida or anencephaly, birth defects of the brain or spinal cord.”  
| Must also include information on the multifactorial nature of neural tube defects, and the safe upper limit of daily intake. | Healthful diets with adequate folate may reduce a woman's risk of having a child with a brain or spinal cord defect. |
### Appendix IV: Health Claims That May Be Used On Food Labels

<table>
<thead>
<tr>
<th>Food/disease risk</th>
<th>Claim requirements</th>
<th>Model claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dietary noncariogenic carbohydrate sweeteners/dental caries</td>
<td>Required terms:</td>
<td>Full claim: Frequent between-meal consumption of foods high in sugars and starches promotes tooth decay. The sugar alcohols in [name of food] do not promote tooth decay.</td>
</tr>
<tr>
<td></td>
<td>“Does not promote,” “may reduce the risk of,” “useful [or is useful] in not promoting,” or “expressly [or is expressly] for not promoting” dental caries.</td>
<td>Shortened claim (on small packages only): Does not promote tooth decay.</td>
</tr>
<tr>
<td></td>
<td>“Dental caries,” or “tooth decay.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>“Sugar alcohol” or “sugar alcohols” or the name or names of the sugar alcohols; or D-tagatose, or sucralose.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Note: D-tagatose may be identified as “tagatose.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>When the substance that is the subject of the claim is a noncariogenic sugar (i.e., D-tagatose) the claim shall identify the substance as a sugar that, unlike other sugars, does not promote the development of dental caries.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Includes statement that frequent between-meal consumption of foods high in sugars and starches can promote tooth decay.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Packages with less than 15 square inches of surface area available for labeling may use a shortened claim.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soluble fiber from certain foods/coronary heart disease</td>
<td>Required terms:</td>
<td>Soluble fiber from foods such as [name of soluble fiber source], and, if desired, name of food product, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. A serving of [name of food product] supplies __ grams of the [necessary daily dietary intake for the benefit] soluble fiber from [name of soluble fiber source] necessary per day to have this effect.</td>
</tr>
<tr>
<td></td>
<td>“Heart disease” or “coronary heart disease.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>“Saturated fat” and “cholesterol.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>In specifying the substance the claim uses the term “soluble fiber” qualified by the name of the eligible source of the soluble fiber, which is either whole oat or barley or psyllium seed husk.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claim specifies the daily dietary intake of the soluble fiber source necessary to reduce the risk of coronary heart disease.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claim specifies the amount of soluble fiber in one serving of the product.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Additional required label statement:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foods bearing a psyllium seed husk health claim must also bear a label statement concerning the need to consume them with adequate amounts of fluids; e.g., “NOTICE: This food should be eaten with at least a full glass of liquid. Eating this product without enough liquid may cause choking. Do not eat this product if you have difficulty in swallowing.”</td>
<td></td>
</tr>
</tbody>
</table>
## Appendix IV: Health Claims That May Be Used On Food Labels

<table>
<thead>
<tr>
<th>Food/disease risk</th>
<th>Claim requirements</th>
<th>Model claim</th>
</tr>
</thead>
</table>
| Soy protein/coronary heart disease | **Required terms:**  
“Heart disease” or “coronary heart disease.”  
“Soy protein.”  
“Saturated fat” and “cholesterol.”  
Claim specifies daily dietary intake levels of soy protein associated with reduced risk.  
Claim specifies amount of soy protein in a serving of food.  
| (1) Twenty-five grams of soy protein a day, as part of a [diet] low in saturated fat and cholesterol, may reduce the risk of heart disease. A serving of [name of food] supplies ___ grams of soy protein.  
(2) Diets low in saturated fat and cholesterol that include 25 grams of soy protein a day may reduce the risk of heart disease. One serving of [name of food] provides ___ grams of soy protein. |
| Plant sterol/stanol esters/coronary heart disease | **Required terms:**  
“May” or “might” reduce the risk of coronary heart disease.  
“Heart disease” or “coronary heart disease,”  
“Plant sterol esters” or “plant stanol esters”; except “vegetable oil” may replace the term “plant” if vegetable oil is the sole source of the sterol/stanol ester.  
Claim specifies plant sterol/stanol esters are part of a diet low in saturated fat and cholesterol.  
Claim does not attribute any degree of coronary heart disease risk reduction.  
Claim specifies the daily dietary intake of plant sterol or stanol esters necessary to reduce coronary heart disease risk, and the amount provided per serving.  
Claim specifies that plant sterol or stanol esters should be consumed with two different meals each a day.  
| (1) Foods containing at least 0.65 grams per [serving] of vegetable oil sterol esters, eaten twice a day with meals for a daily total intake of least 1.3 grams, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. A serving of [name of food] supplies ___ grams of vegetable oil sterol esters.  
(2) Diets low in saturated fat and cholesterol that include two servings of foods that provide a daily total of at least 3.4 grams of plant stanol esters in two meals may reduce the risk of heart disease. A serving of [name of food] supplies ___ grams of plant stanol esters. |

Source: FDA.
### Table 6: Five Health Claims Based on Authoritative Statements That May Be Used on Food Labels

<table>
<thead>
<tr>
<th>Food/disease risk</th>
<th>Food requirements</th>
<th>Required wording of health claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole grain foods/reduced risk of heart disease and certain cancers</td>
<td>Contains 51 percent or more whole grain ingredients by weight per referenced amount customarily consumed (RACC), and Dietary fiber content at least: 3.0 grams (g) per RACC of 55 g 2.8 g per RACC of 50 g 2.5 g per RACC of 45 g 1.7 g per RACC of 35 g Low fat</td>
<td>Diets rich in whole grain foods and other plant foods and low in total fat, saturated fat, and cholesterol may reduce the risk of heart disease and some cancers.</td>
</tr>
<tr>
<td>Potassium/reduced risk of high blood pressure and stroke</td>
<td>Good source of potassium. Low sodium. Low total fat. Low saturated fat. Low cholesterol.</td>
<td>Diets containing foods that are a good source of potassium and that are low in sodium may reduce the risk of high blood pressure and stroke.</td>
</tr>
<tr>
<td>Fluoridated water/reduced risk of dental caries</td>
<td>Bottled water meeting the standards of identity and quality set forth in 21 CFR 165.110 Meet all general requirements for health claims in 21 CFR 101.14) with the exception of the minimum nutrient contribution (21 CFR 101.14(e)(6)) Total fluoride &gt;0.6 to 1.0 mg/L. Excluding bottled water products specifically marketed for use by infants.</td>
<td>Drinking fluoridated water may reduce the risk of [dental caries, or tooth decay].</td>
</tr>
<tr>
<td>Saturated fat, cholesterol, and trans fat/reduced risk of heart disease.</td>
<td>Low saturated fat. Low cholesterol. Bear quantitative trans fat labeling. Contain less than 0.5 g trans fat per RACC. Contain less than 6.5 g total fat.</td>
<td>Diets low in saturated fat and cholesterol, and as low as possible in trans fat, may reduce the risk of heart disease.</td>
</tr>
<tr>
<td>Substitution of saturated fat with unsaturated fatty acids/reduced risk of heart disease</td>
<td>Vegetable oils, spreads, and shortenings that have a total unsaturated fat content of 80 percent or more of total fat.</td>
<td>Replacing saturated fat with similar amounts of unsaturated fats may reduce the risk of heart disease. To achieve this benefit, total daily calories should not increase.</td>
</tr>
</tbody>
</table>

Source: FDA.
FDA launched an initiative to address claim violations in food labeling in late 2009 and early 2010 in which it issued 17 warning letters and an untitled letter informing companies that the claims on their product labels and/or Web sites violated FDA’s food labeling statutes and regulations. Two of the 17 warning letters were for qualified health claims violations and are summarized in table 4 of this report. The remaining 15 warning letters and the untitled letter are summarized in table 7.

Table 7: Other Warning Letters and the Untitled Letter FDA Issued for Labeling Claim Violations, December 2009 through February 2010

<table>
<thead>
<tr>
<th>Action</th>
<th>Company (date of letter)</th>
<th>Product and/or product line</th>
<th>Violation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warning letters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nestle USA (Dec. 4, 2009)</td>
<td></td>
<td>Juicy Juice Brain Development Fruit Juice Beverage (Apple)</td>
<td>The product makes claims such as “no sugar added,” which are not allowed on products intended for children under 2 years of age because appropriate dietary levels have not been established for children in this age range.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Juicy Juice All-Natural 100% Juice Orange Tangerine; Juicy Juice All-Natural 100% Juice Grape</td>
<td>The product labels imply that the products are 100 percent juice when they are actually juice blends with added flavors.</td>
</tr>
<tr>
<td>Nestle Nutrition (Feb. 22, 2010)</td>
<td></td>
<td>Gerber’s 2nd Foods Carrots</td>
<td>The product makes claims such as “healthy,” “excellent source of . . . vitamin A,” and “no added sugar,” which are not allowed on products intended for children under 2 years of age because appropriate dietary levels have not been established for children in this age range.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gerber Graduates Fruit Puffs line</td>
<td>The product makes claims such as “good source of iron, zinc, and vitamin E,” which are not allowed on products intended for children under 2 years of age because appropriate dietary levels have not been established for children in this age range.</td>
</tr>
<tr>
<td>Beech-nut Nutrition Corporation (Feb. 22, 2010)</td>
<td></td>
<td>Beechnut DHA Plus line of products</td>
<td>The product makes claims on its Web site such as “no added refined sugar” and “plus vitamins and minerals,” which are not allowed on products intended for children under 2 years of age because appropriate dietary levels have not been established for children in this age range.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Beechnut Whole Grain Oatmeal with mixed fruit</td>
<td>The product makes claims such as “low sodium,” “plus fiber,” and “plus vitamins &amp; minerals,” which are not allowed on products intended for children under 2 years of age because appropriate dietary levels have not been established for children in this age range.</td>
</tr>
<tr>
<td>Dreyers Grand Ice Cream, Inc. (Feb. 22, 2010)</td>
<td></td>
<td>Nestle Drumstick Classic Vanilla Fudge</td>
<td>The front panel shows that the product has no trans fat, but it does not have a disclosure statement to alert consumers that the product has significant levels of saturated fat and total fat.</td>
</tr>
</tbody>
</table>
## Appendix V: Warning Letters Issued for Claim Violations on Food Labels and Web Sites, December 2009 through February 2010

<table>
<thead>
<tr>
<th>Action</th>
<th>Company (date of letter)</th>
<th>Product and/or product line</th>
<th>Violation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dreyers Dibs Bite Sized Ice Cream Snacks Vanilla Ice Cream with Nestle Crunch Coating</td>
<td>The front panel shows that the product has no trans fat, but it doesn't have a disclosure statement to alert consumers that the product has significant levels of saturated fat and total fat.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>First Juice, Inc. (Feb. 22, 2010)</td>
<td>Organic Fruit and Veggie Juice Beverage products</td>
<td>The product make claims such as &quot;plus calcium,&quot; and &quot;50% less sugar,&quot; which are not allowed on products intended for children under 2 years of age because appropriate dietary levels have not been established for children in this age range.</td>
</tr>
<tr>
<td></td>
<td>Purple carrot products</td>
<td>The products make claims that the products will &quot;reduce the risk of cancer and stroke.&quot; This claim has not been authorized by FDA for use on food products.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gorton’s, Inc. (Feb. 22, 2010)</td>
<td>Gorton’s Beer Battered Crispy Battered Fish Fillets</td>
<td>The front panel shows that the product has no trans fat, but it does not have a disclosure statement to alert consumers that the product has significant levels of sodium, saturated fat, and total fat.</td>
</tr>
<tr>
<td></td>
<td>Guangzhou Yong Want Foods Ltd. (Feb. 22, 2010)</td>
<td>Baby Mum-Mum Original Selected Superior Rice Rusks</td>
<td>The product makes claims such as “low in fat,” and “no added fats for oils,” which are not allowed on products intended for children under 2 years of age because appropriate dietary levels have not been established for children in this age range.</td>
</tr>
<tr>
<td></td>
<td>Ken’s Foods, Inc. (Feb. 22, 2010)</td>
<td>Ken’s Healthy Options™ Dressings Parmesan &amp; Peppercorn; Sweet Vidalia® Onion Vinaigrette; Raspberry Walnut</td>
<td>The product makes claims such as &quot;Healthy Options,&quot; but has more fat than is allowed in products labeled as &quot;healthy.&quot;</td>
</tr>
<tr>
<td></td>
<td>PBM Products, LLC (Feb. 22, 2010)</td>
<td>Parent’s Choice Little Puffs Plus Calcium Blueberry Naturally Flavored product; Parent’s Choice Little Puffs Made With Whole Grains Peach-Mango Naturally Flavored product.</td>
<td>The product makes claims such as “plus calcium,” which are not allowed on products intended for children under 2 yrs of age because appropriate dietary levels have not been established for children in this age range.</td>
</tr>
<tr>
<td></td>
<td>Pompeian, Inc. (Feb. 22, 2010)</td>
<td>Pompeian Imported Extra Light Olive Oil</td>
<td>The product makes nutrient content claims such as “light,” and “high in monounsaturated fat,” but does not meet the requirement to make these claims.</td>
</tr>
<tr>
<td></td>
<td>Redco Foods, Inc. (Feb. 22, 2010)</td>
<td>Salada Naturally Decaffeinated Green Tea</td>
<td>The product makes claims that it will treat, prevent, or cure diseases such as Alzheimer’s disease, rheumatism, and cancer. These types of claims are not allowed on food products.</td>
</tr>
<tr>
<td></td>
<td>Schwan’s Consumer Brands (Feb. 22, 2010)</td>
<td>Mrs. Smith’s Classic Coconut Custard Pie</td>
<td>The front panel shows that the product has no trans fat, but it does not have a disclosure statement to alert consumers that the product has significant levels of saturated fat and total fat.</td>
</tr>
</tbody>
</table>
### Appendix V: Warning Letters Issued for Claim Violations on Food Labels and Web Sites, December 2009 through February 2010

<table>
<thead>
<tr>
<th>Action</th>
<th>Company (date of letter)</th>
<th>Product and/or product line</th>
<th>Violation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Spectrum Organic Products, Inc. (Feb. 22, 2010)</td>
<td>Organic All Vegetable Shortening</td>
<td>The front panel shows that the product has no trans fat, but it does not have a disclosure statement to alert consumers that the product has significant levels of saturated fat and total fat. The product makes nutrient content claims such as “cholesterol free,” “less saturated fat than butter,” and “good source of . . . monounsaturated fat” but does not meet the legal requirements to make these claims.</td>
</tr>
<tr>
<td></td>
<td>Sunsweet Growers, Inc. (Feb. 22, 2010)</td>
<td>Antioxidant Blend Dried Fruit Mix</td>
<td>The product makes claims such as “full of nutritious antioxidants,” but the claim does not meet the requirements of the antioxidant regulation.</td>
</tr>
<tr>
<td></td>
<td>POM Wonderful (Feb. 23, 2010)</td>
<td>POM Wonderful 100% Pomegranate Juice</td>
<td>The product makes claims that it will treat, prevent, or cure diseases such as hypertension, diabetes, and cancer. These types of claims are not allowed on food products.</td>
</tr>
<tr>
<td>Untitled letter</td>
<td>Nature’s Path Foods, Inc. (Feb. 22, 2010)</td>
<td>Organic Flax Plus Multibran Cereal</td>
<td>The product label includes the nutrient claim, &quot;excellent source of Omega-3+,&quot; which has not been approved for use on food products.</td>
</tr>
</tbody>
</table>

Source: GAO analysis of FDA information.
Appendix VI: Comments from the Department of Health and Human Services

DEPARTMENT OF HEALTH & HUMAN SERVICES

DEC 23 2010

Lisa Shames
Director, Natural Resources and Environment
U.S. Government Accountability Office
441 G Street NW
Washington, DC 20548

Dear Ms. Shames:


The Department appreciates the opportunity to review and comment on this draft report prior to publication.

Sincerely,

Jim R. Esquea
Assistant Secretary for Legislation

Attachment

The Department appreciates the opportunity to review and comment on this draft report.

The Food and Drug Administration welcomes this GAO report as a means of calling attention to the extremely complex and challenging legal and regulatory environment under which FDA must work to protect consumers from false and misleading label claims on foods, particularly qualified health claims and structure/function claims. FDA also welcomes this GAO report calling attention to the differences in the legal authorities between FDA and the Federal Trade Commission (FTC) that allow FTC to compel companies to provide the evidence supporting their advertising claims.

In the past several years, FDA has

- Issued two guidance documents addressing the appropriate use of claims on food labels with one focusing on “sugar free” claims. These guidelines were in response to FDA’s Obesity initiative;
- Issued Warning Letters to approximately 29 juice firms that had unapproved health claims on their websites or product labels;
- Issued a Dear Manufacturer Letter on Front of Package Labeling reminding manufacturers of FDA requirements regarding claims;
- Continued to monitor the marketplace for false/misleading health and nutrient content claims on food products in addition to monitoring general false and misleading labeling statements;
- As a result of this monitoring, in March 2010, issued an open letter to industry from FDA Commissioner Margaret Hamburg urging industry to correct labeling violations; and
- In February 2010 as a result of monitoring activities, issued 17 warning letters to companies for a variety of labeling violations, including failure to incorporate mandatory disclaimer statements when making nutrient content claims.

In each of the last 10 years, FDA has accomplished its work related to health claims and qualified health claims by supporting an average 8.1 FTEs (at 1700 hours per FTE) per year at a cost of approximately $1 million per year.
Appendix VI: Comments from the Department of Health and Human Services

GAO Recommendation

To ensure that the health-related claims on food labels are not false or misleading to consumers, we recommend that the Secretary of Health and Human Services direct the Commissioner of FDA to take the following three actions:

- Identify and request from Congress the authorities needed to access evidence from food companies regarding potentially false or misleading structure/function or other claims on food that would allow the agency to establish whether there is scientific support for the claims.

FDA Response

The agency would like to clarify the scope of its current statutory authority with respect to health claims, nutrient content claims, and structure/function claims.

FDA currently reviews the supporting scientific evidence for health claims and for nutrient content claims. Specifically, for health claims subject to section 403(c) of the Federal Food, Drug, and Cosmetic Act (the Act), those who want to use a health claim in food labeling must submit the evidence used to support the claim through the Nutrition Labeling and Education Act (NLEA) petition process, or they may notify the agency of the claim under the Food and Drug Administration Modernization Act (FDAMA) authoritative statement notification process. Under the petition process for health claims in 21 CFR 101.70, a petitioner must submit a summary of scientific data that provides the basis upon which an authorized health claim can be justified. FDA also expects a company that wishes to make a qualified health claim to submit its supportive evidence in a petition, as described in the agency's 2003 guidance on interim procedures for qualified health claims (see Appendix I, footnote 34).

Similarly, for nutrient content claims subject to section 403(c) of the Act, the data and information that must be submitted to FDA in a petition are set forth in 21 CFR 101.69.

By contrast, companies are currently able to make structure/function claims in the labeling of food without submitting supporting evidence to the FDA for review and without being required to provide such evidence to the agency on request. The agency will work to determine better approaches to enhancing its oversight of structure/function claims, including whether additional statutory authorities are needed.

- Provide guidance to industry on the type and strength of scientific evidence needed to prevent false or misleading information from a structure/function claim.

FDA Response:

FDA supports providing guidance to industry on the type and strength of scientific evidence needed to substantiate a structure/function claim on the label or in the labeling of conventional foods. Currently, FDA has issued guidance for industry
about substantiating structure/function claims made on the label or in the labeling of dietary supplements. As agency priorities and resources permit, FDA will consider development of guidance for industry to substantiate structure/function claims for conventional foods.

- Amend the Compliance Program Guidance Manual instructions to FDA inspectors for reviewing food labels to include steps for identifying potentially false or misleading structure/function claims during inspections of food facilities.

FDA Response:

FDA agrees that field investigators, to whom the Compliance Program Guidance Manual is targeted, have significant exposure to food labels during their routine inspections of food producers. However, the GAO recommendation is impractical, as there are significant challenges to providing specific steps to investigators to identify potentially false or misleading structure/function claims during inspections.

In particular, to judge whether a structure/function claim is false or misleading requires in-depth knowledge of the science that would support or dispute the claim. It would be impossible to provide investigators with the breadth and level of knowledge necessary to make an assessment in the field as to whether any one of the myriad structure/function claims they might encounter on food labels, with all the variations in wording that are possible, is false or misleading. While structure/function claims are not highlighted as an area of emphasis, the Compliance Program Guidance Manual currently includes instructions for inspectors to collect information to determine the extent to which food products are in compliance with all labeling requirements and provides additional references regarding the types of claims permitted on food labels.
Appendix VII: GAO Contact and Staff Acknowledgments

GAO Contact

Lisa Shames, (202) 512-3841 or shamesl@gao.gov

Staff Acknowledgments

In addition to the individual named above, Erin Lansburgh, Assistant Director; Bruce Skud, Analyst-in-Charge; Kevin Bray; Carol Henn; Luann Moy; Beverly Peterson; and Carol Herrnstadt Shulman made key contributions to this report.
GAO’s Mission

The Government Accountability Office, the audit, evaluation, and investigative arm of Congress, exists to support Congress in meeting its constitutional responsibilities and to help improve the performance and accountability of the federal government for the American people. GAO examines the use of public funds; evaluates federal programs and policies; and provides analyses, recommendations, and other assistance to help Congress make informed oversight, policy, and funding decisions. GAO’s commitment to good government is reflected in its core values of accountability, integrity, and reliability.

Obtaining Copies of GAO Reports and Testimony

The fastest and easiest way to obtain copies of GAO documents at no cost is through GAO’s Web site (www.gao.gov). Each weekday afternoon, GAO posts on its Web site newly released reports, testimony, and correspondence. To have GAO e-mail you a list of newly posted products, go to www.gao.gov and select “E-mail Updates.”

Order by Phone

The price of each GAO publication reflects GAO’s actual cost of production and distribution and depends on the number of pages in the publication and whether the publication is printed in color or black and white. Pricing and ordering information is posted on GAO’s Web site, http://www.gao.gov/ordering.htm.

Place orders by calling (202) 512-6000, toll free (866) 801-7077, or TDD (202) 512-2537.

Orders may be paid for using American Express, Discover Card, MasterCard, Visa, check, or money order. Call for additional information.

To Report Fraud, Waste, and Abuse in Federal Programs

Contact:

E-mail: fraudnet@gao.gov
Automated answering system: (800) 424-5454 or (202) 512-7470

Congressional Relations

Ralph Dawn, Managing Director, dawnr@gao.gov, (202) 512-4400
U.S. Government Accountability Office, 441 G Street NW, Room 7125
Washington, DC 20548

Public Affairs

Chuck Young, Managing Director, youngc1@gao.gov, (202) 512-4800
U.S. Government Accountability Office, 441 G Street NW, Room 7149
Washington, DC 20548

Please Print on Recycled Paper